

World Journal of *Otorhinolaryngology*

World J Otorhinolaryngol 2013 November 28; 3(4): 114-133



**REVIEW**

114 Nanoparticle based inner ear therapy

Pyykkö I, Zou J, Zhang Y, Zhang W, Feng H, Kinnunen P

Contents

World Journal of Otorhinolaryngology
Volume 3 Number 4 November 28, 2013

APPENDIX I-V Instructions to authors

ABOUT COVER Editorial Board Member of *World Journal of Otorhinolaryngology*, Sheng Hwa Chen, PhD, CCC-SLP, Professor, Department of Speech and Hearing Disorders and Sciences National Taipei University of Nursing and Health Sciences, #31, 7F, Alley 117, Lane 52, Tien-Mu West Road, Peitou 112 Taipei, Taiwan

AIM AND SCOPE *World Journal of Otorhinolaryngology* (*World J Otorhinolaryngol*, *WJO*, online ISSN 2218-6247, DOI: 10.5319) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJO covers topics concerning endoscopy, rhinology, pharyngology, laryngology, tracheoesophagology, otology, tracheology, cancer, nasal symptomatology, congenital nasal diseases, inflammatory diseases of the external nose, rhinitis, allergic rhinitis, nasal polyps, nasal septal diseases, nasal bleeding, nasal or sinus foreign bodies, sinusitis, rhinogenic complications, diagnostic imaging, evidence-based medicine, epidemiology and nursing. Priority publication will be given to articles concerning diagnosis and treatment of otorhinolaryngologic diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to WJO. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING *World Journal of Otorhinolaryngology* is now indexed in Digital Object Identifier.

FLYLEAF I-II Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xin-Xing Che*
Responsible Electronic Editor: *Ya-Jing Lu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xue-Mei Cui*

NAME OF JOURNAL
World Journal of Otorhinolaryngology

ISSN
ISSN 2218-6247 (online)

LAUNCH DATE
December 28, 2011

FREQUENCY
Quarterly

EDITOR-IN-CHIEF
Tsutomu Nakashima, MD, PhD, Professor, Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

Steven J Wang, MD, FACS, Associate Professor in Residence, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, 2233 Post St, 3rd Floor-Box 1225, San Francisco, CA 94115, United States

EDITORIAL OFFICE
Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director
World Journal of Otorhinolaryngology
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: bpgooffice@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza,
315-321 Lockhart Road, Wan Chai,
Hong Kong, China
Fax: +852-6555-7188
Telephone: +852-3177-9906
E-mail: bpgooffice@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
November 28, 2013

COPYRIGHT
© 2013 Baishideng Publishing Group Co., Limited. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/2218-6247/g_info_20100722180338.htm

ONLINE SUBMISSION
<http://www.wjgnet.com/esps/>



World Journal of Otorhinolaryngology

A peer-reviewed, online, open-access journal of otorhinolaryngology

Editorial Board

2011-2015

The *World Journal of Otorhinolaryngology* Editorial Board consists of 159 members, representing a team of worldwide experts in otorhinolaryngology. They are from 29 countries, including Australia (1), Austria (2), Belgium (5), Brazil (2), China (9), Colombia (1), Czech Republic (1), Denmark (1), Egypt (6), Germany (8), Greece (8), Hungary (1), India (12), Iran (4), Israel (6), Italy (14), Japan (7), New Zealand (1), Nigeria (1), Norway (1), Poland (1), Singapore (2), South Korea (4), Spain (3), Sweden (1), Switzerland (1), Turkey (15), United Kingdom (4), and United States (37).

EDITORS-IN-CHIEF

Tsutomu Nakashima, *Nagoya*
Steven J Wang, *San Francisco*

GUEST EDITORIAL BOARD MEMBERS

Mu-Kuan Chen, *Changhua*
Sheng Hwa Chen, *Taipei*
Tuan-Jen Fang, *Keelung*
Chao-Cheng Huang, *Kaohsiung*
Hsin-Ching Lin, *Kaohsiung*

MEMBERS OF THE EDITORIAL BOARD



Australia

Anne Elizabeth Vertigan, *Newcastle*



Austria

Christoph Arnoldner, *Vienna*
Dietmar Thurnher, *Vienna*



Belgium

Philippe Henri Dejonckere, *Brussels*
Joris Joris Dirckx, *Antwerp*
Amr Essam El-Shazly, *Liege*
Philippe Rombaux, *Brussels*
Robby Vanspauwen, *Antwerp*



Brazil

Maria Cristina Chammas, *São Paulo*
Etienne de Andrade Munhoz, *Porto Alegre*



China

Anna Chishan Kam, *Hong Kong*
Hua-Bin Li, *Guangzhou*
Jian-Chun Liao, *Shanghai*
Zheng Liu, *Wuhan*



Colombia

Luis M Ramirez Aristeguieta, *Medellin*



Czech Republic

Jan Vodicka, *Pardubice*



Denmark

Jesper Dammeyer, *Copenhagen*



Egypt

Tarek Abdelhameed Abulezz, *Sohag*
Omar A El-Banhawy, *El-Dakahlia*
Sherifa Ahmed Hamed, *Assiut*
Emad Ahmed Magdy, *Alexandria*
Badr Eldin Mostafa, *Cairo*
Sameh Ibrahim Sersar, *Mansoura*



Germany

Andreas Bahmer, *Frankfurt am Main*
Carsten Christof Boedeker, *Freiburg*

Raphael Richard Cuman, *Gelsenkirchen*
Jessica Freiherr, *Aachen*
Haralampos Gouveris, *Mainz*
Markus Hambek, *Frankfurt*
Hamidreza Mojallal, *Hannover*
Leif Erik Walther, *Sulzbach*



Greece

Anna Eleftheriadou, *Rethymnon*
Tsakiropoulou Evangelia, *Thessaloniki*
G Michael-Minas Fragkiadakis, *Heraklion*
Vasiliki Vivian Iliadou, *Thessaloniki*
Alexander Dimitrios Karatzanis, *Heraklion*
George I Noussios, *Serres*
Theodossis S Papavramidis, *Thessaloniki*
Maria George Riga, *Alexandroupolis*



Hungary

László Robert Rovó, *Szeged*



India

Prakash Singh Bisen, *Jhansi*
Muthuswamy Dhiwakar, *Coimbatore*
Prahald Duggal, *Amritsar*
Bulbul Gupta, *Delhi*
Ajith Kumar U, *Mysore*
Satish Nair, *Delhi Cantt*
Vijaya Kumar Narne, *Mysore*
Ravi Chandran Nayar, *Bangalore*
Ashwani Sethi, *New Delhi*
Ashok Kumar Sinha, *Kolkata*
Alok Thakar, *New Delhi*
Jagdeep S Thakur, *Shimla*

**Iran**

Fatemeh Hassannia, *Tehran*
 Mohsen Naraghi, *Tehran*
 Mehrdad Nooranipour, *Tehran*
 Mohammad Sadeghi, *Tehran*

**Israel**

Itzhak Braverman, *Hadera*
 Haim Gavriel, *Zerifin*
 Menachem Gross, *Jerusalem*
 Avi Hefetz Khafif, *Ramat-Hasharon*
 Daniel M Kaplan Mha, *Omer*
 Michael Vaiman, *Bat Yam*

**Italy**

Marco Berlucchi, *Brescia*
 Giovanni Blandino, *Rome*
 Francesco Bussu, *Rome*
 Giuseppe Caruso, *Siena*
 Alessandro De Stefano, *Taranto*
 Alberto Deganello, *Florence*
 Francesco Dispenza, *Palermo*
 Alfio Ferlito, *Udine*
 Alessandro Franchi, *Florence*
 Paolo Gasparini, *Trieste*
 Dario Gregori, *Padova*
 Stavros D Hatzopoulos, *Ferrara*
 Gino Marionni, *Padova*
 Giacomo Pata, *Brescia*

**Japan**

Arata Horii, *Osaka*
 Sho Kanzaki, *Tokyo*
 Nejat Mahdih, *Shizuoka*
 Nobuhiko Oridate, *Sapporo*
 Akihiro Shiotani, *Saitama*
 Keiji Tabuchi, *Tsukuba*

**New Zealand**

Srdjan Vlajkovic, *Auckland*

**Nigeria**

Bolajoko O Olusanya, *Lagos*

**Norway**

Vinay Swarnalatha Nagaraj, *Trondheim*

**Poland**

W Wiktor Jedrzejczak, *Warsaw*

**Singapore**

Gopalakrishna Iyer, *Singapore*
 De-Yun Wang, *Singapore*

**South Korea**

Yong Ju Jang, *Seoul*
 Han Su Kim, *Seoul*
 Sang Hag Lee, *Seoul*
 Raekil Park, *Iksan*

**Spain**

Mario A Hermesen, *Oviedo*
 Adolfo Toledano Muñoz, *Alcorcón*
 Enrique Zapater-Latorre, *Valencia*

**Sweden**

Zhe Jin, *Uppsala*

**Switzerland**

Thomas Nicola Roth, *Zurich*

**Turkey**

Atilla Arslanoglu, *Ankara*
 Murat Caloglu, *Edirne*
 Ali Coskun, *Izmir*
 Alper Nabi Erkan, *Adana*
 Muhammed Fatih Evcimik, *Istanbul*
 Mustafa Gul, *Kahramanmaraş*
 Mehmet Gunduz, *Ankara*
 Samet Vasfi Kuvat, *Istanbul*
 Nuray Bayar Muluk, *Ankara*

Nesrin Bozdogan Ozyilkan, *Adana*
 Murat Songu, *Izmir*
 Rauf Tahamiler, *Istanbul*
 Murat Unal, *Mersin*
 Sidika Deniz Micozkadioglu Yalim, *Adana*
 Yavuz Selim Yildirim, *Istanbul*

**United Kingdom**

Ruth Epstein, *London*
 Ahmed Eweiss, *Gloucester*
 Jonathan Charles Hobson, *Manchester*
 Petros V Vlastarakos, *Stevenage*

**United States**

Ahmed Kamel Abdel Aal, *Birmingham*
 Thomas Jay Balkany, *Miami*
 Samuel S Becker, *Sewell*
 Annie W Chan, *Boston*
 Rakesh Kumar Chandra, *Chicago*
 Allen M Chen, *Sacramento*
 Nipun Chhabra, *Cleveland*
 Donald E Coling, *Buffalo*
 Didier A Depireux, *College Park*
 Dalian Ding, *New York*
 Richard L Doty, *Philadelphia*
 James Paul Dworkin, *Detroit*
 Ivan H El-Sayed, *San Francisco*
 Bharat Guthikonda, *Baton Rouge*
 Patrick Kyongmin Ha, *Baltimore*
 Jeffrey Allen Koempel, *Los Angeles*
 Kevin W Lollar, *Columbia*
 Lori Lombard, *Indiana*
 Ron B Mitchell, *St Louis*
 Larry Leonard Myers, *Dallas*
 Kevin K Ohlemiller, *Saint Louis*
 Fred A Pereira, *Houston*
 Sonja J Pyott, *Wilmington*
 Sophia Ran, *Springfield*
 Claus-Peter Richter, *Chicago*
 James M Ridgway, *Seattle*
 Richard Allen Roberts, *Foley*
 Peter S Roland, *Dallas*
 Soya Sisy Sam, *Saginaw*
 Chris A Sanford, *Pocatello*
 Ashok R Shaha, *New York*
 Abraham Shulman, *Brooklyn*
 Jeffrey Howard Spiegel, *Boston*
 Rohan R Walvekar, *New Orleans*
 Gregory Thomas Wolf, *Ann Arbor*
 Kathleen Yaremchuk, *Detroit*

Nanoparticle based inner ear therapy

Ilmari Pyykkö, Jing Zou, Ya Zhang, Weikai Zhang, Hao Feng, Paavo Kinnunen

Ilmari Pyykkö, Jing Zou, Ya Zhang, Weikai Zhang, Hao Feng, Department of Otolaryngology, Hearing and Balance Research Unit, University Hospital of Tampere, 33520 Tampere, Finland

Ya Zhang, Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

Weikai Zhang, Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

Paavo Kinnunen, Department of Biomedical Engineering and Computational Science, Aalto University, 02150 Esbo, Finland

Author contributions: Pyykkö I and Zou J designed the research; Zhang Y, Zhang W and Feng H performed *in vitro* and *in vivo* experiments on selected nanoparticles; Kinnunen P designed and produced the lipoplexes; Zou J analyzed data; Pyykkö I wrote the paper.

Supported by EU Nanoeur Integrated Project NMP4-CT-2006-026556; and EU NanoCI Collaborative Project FP7 281056

Correspondence to: Ilmari Pyykkö, Professor, Department of otolaryngology, Hearing and Balance Research Unit, University of Tampere, Teiskontie 35, M-building Room 318, 33520 Tampere, Finland. ilmari.pyykk@uta.fi

Telephone: +358-3-31166387 Fax: +358-3-31164366

Received: May 5, 2013 Revised: August 22, 2013

Accepted: October 17, 2013

Published online: November 28, 2013

Abstract

Synthetic nanoparticles can be used to carry drugs, genes, small interfering RNA (siRNA) and growth factors into the inner ear, to repair, restore and induce cellular regeneration. Nanoparticles (NPs) have been developed which are targetable to selected tissue, traceable *in vivo*, and equipped with controlled drug/gene release. The NPs are coated with a "stealth" layer, and decorated with targeting ligands, markers, transfection agents and endosomal escape peptides. As payloads, genes such as the *BDNF*-gene, *Math1*-gene and *Prestin*-gene have been constructed and delivered *in vitro*. Short-hairpin RNA has been used *in vitro* to silence the negative regulator of Math1, the inhibitors of differentiation and DNA binding. In order to facilitate the passage of cargo from the middle ear to

the inner ear, the oval window transports gadolinium chelate more efficiently than the round window and is the key element in introducing therapeutic agents into the vestibule and cochlea. Depending upon the type of NPs, different migration and cellular internalization pathways are employed, and optimal carriers should be designed depending on the cargo. The use of NPs as drug/gene/siRNA carriers is fascinating and can also be used as an intraoperative adjunct to cochlear implantation to attract the peripheral processes of the cochlear nerve.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Synthetic vector; Gene delivery; shRNA delivery; Targeted cochlear therapy; Minimally invasive therapy

Core tip: Several novel, multifunctional nanoparticles have been developed, which are targetable to selected tissue, biodegradable, traceable *in vivo*, and equipped with controlled payload release. They can be used to transport therapeutic agents, such as drugs, genes, small interfering RNAs and growth factors into the inner ear. To visualise the targetability and accuracy of the delivery, the nanoparticles can be traced with magnetic resonance imaging. It is hoped that this technology will come to be used as an alternative carrier to viral vectors traditionally used in gene delivery, but without the severe adverse effect.

Pyykkö I, Zou J, Zhang Y, Zhang W, Feng H, Kinnunen P. Nanoparticle based inner ear therapy. *World J Otorhinolaryngol* 2013; 3(4): 114-133 Available from: URL: <http://www.wjgnet.com/2218-6247/full/v3/i4/114.htm> DOI: <http://dx.doi.org/10.5319/wjo.v3.i4.114>

INTRODUCTION

Hearing loss is the leading birth defect in western societ-




Figure 1 Histology of cochlea and targets for cell specific pharmacogene therapy. Three fluid filled compartments characterize the mammalian hearing organ. Nerve fibres and neurons (Spiral ganglion, peripheral processes and central processes), sensory epithelium (Corti's organ). Tyrosine kinase B receptor (TrkB) is indicated as a target for therapy.

ies affecting 2-3 children per 1000 born. In the EU more than 60 million people are affected by hearing loss and hearing loss is rated as the 9th most severe disease. The burden of the hard of hearing is considerable, in terms of physical, social and mental well-being, educational development and employment^[1]. In the United States people with hearing impairment represent an economic cost estimated at €222.4 billion and in the EU the costs of hearing deficit are second only to brain disorders (€ 386 billion). Moreover, because of the increasing age of population, the developed world will face an increasing number of hearing handicaps^[2]. For mild to moderate forms of hearing impairment, conventional hearing aids alleviate communication problems in hearing loss. In severe hearing loss and deafness however, auditory function can only be restored by insertion of a neuro-prosthesis that functionally replaces the lost inner ear sensory cells by directly stimulating the auditory neurons. By using a cochlear implant, formerly deaf or deaf-born children can achieve functional hearing and learn to communicate with speech, and over 150000 devices are currently in use worldwide. We now know that many of these hearing impairments can be significantly alleviated with targeted drug delivery.

The inner ear has been a difficult organ to access therapeutically, due to membrane based partitioning, protected sensory cells and neural elements and its closed fluid dynamics (Figure 1). Nevertheless, the relative isolation, low immunoreactivity, availability of quantitative and objective measures of function, and the new imaging measures available for the inner ear, makes it an ideal test model by which to assess the efficacy and safety of putative therapeutic interventions, applied locally and based on the use of nanoparticle delivery systems. Moreover, cochlear implant surgery offers the opportunity of direct access in a low risk (deafened) ear for the eventual clinical testing of the nanotechnology based targeted drug delivery.

The inner ear comprises the vestibular apparatus for balance control and the coiled cochlea. Sound enters the cochlea through tympanic membrane that mediates

the compression waves in the air to vibration of the ossicular chain. The vibration enters along ossicular chain to the oval window that forces the fluid in the scala vestibuli to vibrate in the same phase. The scala vestibule is confluent on the apical tip with the scala tympani and contains perilymph. The vibration activates the separate membrane covered fluid space of scala media containing the organ of Corti. In the organ of Corti the sensory epithelium consists of three rows of outer hair cells and one row of inner hair cells. Isolated by the tectorial membrane and the basilar membrane the Corti's organ is bathed in the endolymph of the scala media.

The hair cells convert sound into electrical signals and wind up 32-40 mm two and a half turns around the spindle shaped modiolus that houses the spiral ganglion cells containing the primary neurons. The sensory epithelium contains one row of inner hair cells and 3-4 rows of outer hair cells, and rests on the basilar membrane. This membrane vibrates when stimulated by sound in a tonotopic manner; high frequencies show maximum vibration in the basal part whilst low frequencies are mapped in the apical regions. The motile outer hair cells actively tune the displacement of the basilar membrane and thereby amplify and sharpen the pitch discrimination. A loss of hair cells and a retrograde degeneration of spiral ganglion cells lead to irreversible hearing loss. Cochlear implants can partly supplement the lost hair cells by direct electrical stimulation of the cochlear nerve. The inner ear is therefore an attractive model organ for treatment as it contains circumscriptive sensory elements, as well as neurons and vasculature that can be systematically analysed.

The application of a novel drug or gene therapy into the inner ear is hindered by a lack of vectors that are safe, efficacious and cell/tissue-selective^[3-5]. To treat the "difficult-to-reach" tissues of the inner ear, different efforts have been tried such as the use of bio-implantable drug reservoirs^[6], implantable catheters with a drug reservoir^[4], viral carriers for DNA^[7] and plasmids^[8], and the recent development of synthetic vectors^[4]. Viruses offer their own set of safety limitations for wider use. Implantable drug reservoirs have been of limited success and been mainly used for the delivery of corticosteroids on the round window membrane (RWM)^[9]. There are also an abundance of commercially available plasmid vectors, that express the selected drug/DNA (albeit in a very transient manner) in the inner ear^[10,11]. Some newer plasmids can penetrate the cell membrane, integrated in the cell genome (episomatic presentation) and remain for a longer period than conventional plasmids^[12,13] but still the efficacy of this delivery mode is limited. This factor however provides an opportunity for synthetic vectors to be used as a future drug carrier to improve safety.

NANOPARTICLES: SIZE AND ADMINISTRATION IN INNER EAR THERAPY

The first nanoparticles were developed in the 1950s, but

Table 1 Illustration of average size of different object with reference to nanoparticles

Object	Size (nm)
Red blood cell	7000
Bacterium	1000
Virus	70-150
Nanoparticle	20-100
Gadolinium chelate	15
Width of DNA	2.5
Aspirin molecule	1

have been used for therapeutic applications only over the past two decades^[14]. Drugs and genes have been recently successfully encapsulated within nanoparticles for the purpose of prolonging the circulation time of therapeutics and to protect them from enzymatic destruction^[15]. Different types of nanoparticles have been developed to treat cancer, pain, and infections, as well as age-related and inherited diseases^[14,16-19]. Due to an increased porosity of the blood vessels in cancer tissue, nanoparticles accumulate in cancer cells. Nanoparticle-based anticancer drugs have shown less adverse effects than non-encapsulated drugs, for example in the case of doxorubicin^[20]. For inner ear drug delivery, nanoparticles have been functionalized with peptides to achieve targeting.

Usually, a batch of nanoparticles has a wide and non-uniform size distribution and this size pattern is usually described as a dispersity index. Some nanoparticles can be very tiny and the largest may exceed a micrometre in size. Particles below 1 nm may be excluded in order to avoid mixing them with the terms of clusters of atoms (Table 1). Biologically however, if the particle size is less than 5 nm then they tend to pass through cell membranes and structures without any obstruction. When the particle size increases, different uptake mechanisms are involved in cellular entry and intracellular trafficking and these play an important role. There is no accepted international definition of a nanoparticle size, but one offered in the new PAS71 document developed in the United Kingdom is: “A particle having one or more dimensions of the order of 100 nm or less” (PAS 71:2011 Vocabulary-Nanoparticles). The ASTM standard also defines that two or three dimensions must be between 1-100 nm (ASTM 2456-06). The current agreement amongst the standards groups is that a scale from 1-100 nm defines the size range of a nanoparticle (ISO ISO/TS 27687:2008). This provides for example for carbon nanotubes to be included as a nanostructure. Their diameters are less than 100 nm but the length may vary from 200 to 2000 nm. Due to their diameter however, they biologically act as nanostructure, therefore a loose definition of size is more applicable to nanoparticles.

Choosing an appropriate delivery method is necessary for the efficient distribution of therapeutic agents in the inner ear while minimizing any adverse effects. The low delivery efficacy and the associated adverse effects of systemic administration however, do not make

this method an ideal treatment for inner ear diseases^[21,22]. Topical RWM surface delivery has proved moderately efficient, and systemic delivery has the lowest efficiency^[23,24]. Local drug RWM delivery is now used extensively in the clinic for treating and diagnosing diseases^[22,25]. At present, intracochlear delivery through cochleostomy appears to be the most effective method for delivering nanoparticles to cochlear cells^[24], however cochleostomy can be performed only under certain circumstances as it can potentially result in inner ear damage.

BASIC CONSTRUCTS OF NANOPARTICLES FOR INNER EAR THERAPY

The characteristics of nanoparticles are determined by specific chemical compositions (Figure 2). Nanoparticles can be produced by a variety of techniques including interfacial deposition, emulsion or sonication. Polymer matrices currently used for drug delivery include polylactic-co-glycolic acid (PLGA), polylactic acid (PLA), polyε-caprolactone (PCL), polyethylene glycol (PEG), silica and chitosan. PLGA, PCL, PEG and PLA are biodegradable and FDA approved polymers, but typically suffer from low drug incorporation efficacy and rapid drug release rates for organic molecules with low molecular weight. Other materials such as silica based materials and chitosan may be manufactured with better incorporation and slower release rates, but may suffer from poorer biodegradability or biocompatibility^[6]. Composite nanoparticles are composed of two block copolymers, *e.g.*, AB-type PLLA-PEG and ABA-type PLLA-PEG-PLLA. These nanostructures may be constructed as “shell-in-shell” nanospheres using, *e.g.*, PLLA-PEG@PNIPAAm-PDLA, containing the drug inside PNIPAAm-PDLA nanospheres which can be released at a specific temperature. Combinations of different isomers are used in order to manipulate the degree of porosity and rate of degradability of the matrix. Besides containing the drug, the composite nanoparticles can also incorporate environment-sensitive components and visualization agents (either as MRI-contrast agents or fluorescent materials).

Liposomes

Liposomes (termed as lipoplexes when containing the payload) are the most common nanoparticles. They are composed of a dual lipid layer with a hydrophilic component outside and inside and a hydrophobic component in the middle^[26]. The core or outer surface of liposomes can carry hydrophilic drugs and genes whereas the bipolar lipid layer can carry hydrophobic drugs. In designing the liposomes, appropriate amounts of the desired lipid stock solution and the indicated lipid-peptide conjugate are mixed to obtain the desired composition. For lipoplexes used in inner ear drug delivery, the lipid films are composed of Sph, eggPC, DSPE-PEG-2000, peptide-PEG-lipid conjugate, and DPPRho. The solvents are thereafter removed and mixed with the cargo




Figure 2 Examples of nanoparticles. The 3G-multifunctional nanoparticle (MFNP) indicates the functionalized third generation multifunctional nanoparticle. The red dots indicate drug/gene incorporation. The respective nanoparticle sizes are shown for each nanoparticle (NP).

by ultrasound^[10,27].

Amorphous silica

Amorphous silica based nanoparticles are biocompatible and biodegradable. These nanoparticles represent a new class of mesoporous materials, which exhibit a high surface area and pore volume, in combination with a tuneable pore size in the range of 2-15 nm. Furthermore, the particle sizes can also be tuned and it is possible to synthesize nanostructures with a size range of 30-1000 nm particles in diameter, with a narrow particle size distribution. Both direct synthesis methods (wet processing) and spray-drying for the synthesis of mesoporous silica nanoparticles is used^[28].

Polymerosomes

Polymerosomes may have various structures: diblock^[29], triblock^[30] and dendritic copolymers^[31]. Polymerosomes used in inner ear delivery consist of di-block copolymers and have hydrophobic and a hydrophilic components^[32,33]. Polymerosomes have a quite stable structure compared to liposomes; they are stable for several months at 4 °C and release their loaded drugs for up to 5 wk at 37 °C^[34]. Unlike liposomes which self-assemble from low-molecular weight lipids, polymerosomes self-assemble from amphiphilic block copolymers, which

consist of linked hydrophilic and hydrophobic polymer chains. Amphiphiles can self-assemble into spherical micelles, rod micelles^[35] and network phases^[36]. By manipulating the molecular weight of the hydrophobic chain, the size of the polymerosomes and the thickness of the lamella can be modified^[37]. By manipulating the weight fraction of the hydrophilic component in the amphiphilic block copolymer, the morphology of the formations can be modulated^[36,38]. The lamella of the polymerosome is thicker than that of the liposomes, and the aqueous core of the polymerosome can be larger than that of the liposome. The polymerosome lamella can load up to 10 mol% of a hydrophobic substance, and is quite stable at room temperature^[39]. Polymerosomes can be easily loaded with hydrophilic and hydrophobic molecules in their internal cavity and their membrane respectively^[39,40].

Chitosan

Chitosan is a natural polymer consisting of a biodegradable polysaccharide primarily consisting of chains formed of *N*-glucosamine units. Due to its polycationic nature, chitosan has been found especially useful in condensating plasmid DNA into particles^[41]. Chitosan nanoparticles are prepared by mixing a solution containing chitosan dissolved in lactic acid and trisodium-polyphosphate solutions, and the variation of the ratio

of the two solutions allows the formation of nanoparticles ranging from 20 to several hundred nanometers, with a narrow size distribution. The fabrication method does not include harsh chemical conditions which may be harmful to the drugs or genes to be incorporated^[41].

Hyperbranched polylysine

Hyperbranched polylysine is based on the dendritic and hyperbranched systems containing poly (α -hydroxy acids) or amino acids. These highly branched polymers are formed by iterative chemical reactions. Such polymers are of a fractal nature, containing a maximum 2D surface area within a minimum 3D space and are below 20 nm in diameter. Poly L-lysine acid forms the polymeric building block as it is possible to produce it with an accurate control of molecular weight, molecular weight distribution and end-group functionality^[42]. The amino acid based hyperbranched polymers can complex with DNA for gene delivery and the manufacturing parameters and composition can be tailored for the desired dendrimer/hyperbranched nanostructure^[42].

Lipidic-core nano-capsules

Lipidic-core nano-capsules (LNCs) are a novel class of very stable nanoparticles, dispersed in aqueous solutions. They are biocompatible and biodegradable molecules and can be fabricated without the use of organic solvents^[43]. The size of LNC nanoparticles can be tailored by the modification of the composition, to the range of 10-200 nm, with a very narrow particle size distribution. The synthesis of LNCs is made possible through the self-organization of poly ethylene glycol like surfactants^[44]. LNCs are constructed as a lipidic core (triglycerides, mineral oils, vitamin A, *etc.*) surrounded by a surfactant shell (stearate of PEG and lecithin), where lecithin is located in the inner part of the shell. The properties of their self PEGylated surface can be tuned simply by the modification of the PEG chain length used. These nanocapsules are particularly suitable for the encapsulation and release of hydrophobic drugs dispersed in the oily core, which makes them excellent candidates for the delivery of drugs and DNA^[45].

FUNCTIONALIZATION OF NANOPARTICLES

Immunoshielding

Although the inner ear is an immune-privileged site, a delayed immune response may occur in the inner ear and lead to an inflammation of the cochlea and vestibule, caused by the nanoparticles. To reduce the opsonization and immune defence, nanoparticles are often coated, commonly with PEG or polyethylene oxide (PEO)^[46]. Coatings can be created in two main ways; by the addition of a PEG containing surfactant at nanoparticle production, or if the nanoparticles are reasonably resistant to aggregation, coating can be performed after

the nanoparticle manufacture^[47]. An alternative method is through the covalent conjugation of PEG to the polymer during particle manufacture^[48]. PEO and PEG tend to repel macromolecules from the coating and reduce contact on the nanoparticle surfaces. The molecular mass and surface density of PEO and PEG molecules^[49,50] must be tailored to achieve a protein repelling effect. Nanoparticle coatings should also inhibit aggregation and reduce non-specific uptake by non-targeted cells^[47]. Unless particles demonstrate significant charge stabilization, they will tend to aggregate, due to their hydrophobicity. Hydrophobic particles and positively charged complexes (for example uncoated polyplexes) will also tend to bind to cell surfaces, which in turn will lead to a non-specific uptake. PEGylated “stealth-nanoparticles” have prolonged circulation times, but can still activate the complement system^[51]. A single intravenous injection of PEGylated liposomes elicited an anti-PEG immunoglobulin M response^[52], similar to that of PEGylated liposomes^[53]. In cancer therapy however, nanoparticles can cause anaphylactic shock by complement activation^[54].

Targeting of nanoparticles

The concept of the specific targeting of nanoparticles to inner ear has been recently introduced^[4]. The surface of nanoparticles is functionalized with targeting moieties, specific to the selected cell population. Previously, antibodies and proteins have been conjugated to nanoparticles to induce a targeted delivery of drugs and genes^[55-57]. To reduce the size of nanoparticles, short peptides have been developed and these suit different targeting purposes^[58]. Cell-penetrating peptides have also been designed to enhance the internalization and cellular penetration of nanoparticles^[59]. The use of short peptides as a targeting moiety is favoured as the immune response is minimal and the increase of the nanoparticles size is a few nanometers. However, the discovery of targeting peptides is both time consuming and laborious work and therefore monoclonal antibodies can provide a more practical choice.

Bitsche *et al.*^[60] demonstrated that at the onset of hearing, TrkB-immunopositive staining occurred in inner hair cells and in cell bodies of the spiral ganglion neurons. TrkC was detected in nerve endings beneath inner and outer hair cells and in supporting cells. Root cells within the spiral ligament and the spiral ganglion neurons in the Rosenthal's canal showed a high level of TrkC expression. The p75 neurotrophin receptor (p75NTR) was found in the organ of Corti similar high rate of expression to TrkC, and scattered neurons showed strong immunoreactivity in the Rosenthal's canal^[61]. Neurotrophic receptors are therefore, attractive targets for inner ear therapy^[44,62-64]. Peptide-functionalized PMs were shown to be capable of targeting specific inner ear cell populations. For example, nerve growth factor-derived peptide-functionalized PEG-*b*-PCL PMs can specifically target the cochlear nerve and SGCs^[44].

Ranjan *et al.*^[27] targeted TrkB positive SH-SY5Y cells using a TrkB ligand (18-mer peptides)-conjugated liposome. Specific binding and augmented uptake were confirmed for TrkB positive SH-SY5Y cells, with the targeting liposome appearing in the cytoplasm after 20 min of incubation. Ranjan *et al.*^[27] demonstrated the feasibility of targeting TrkB-expressing cells with a TrkB ligand conjugated-liposome and the promotion of cellular uptake (entering at least partly into endosomes) *via* receptor-mediated pathways.

Potential targetability with TrkB affinity peptide-functionalized liposome nanoparticles was observed in the adult rat cochlea^[44]. Zou *et al.*^[61] evaluated the internalisation of liposomes functionalized to target TrkB receptors. Roy *et al.*^[44] investigated the utility of nerve growth factor-derived peptide (hNgf-EE) functionalized polymersomes to target the cells of the inner ear. The nanoparticles were introduced to organotypic explant cultures of the mouse inner ear and to rat pheochromocytoma cells (PC-12). Specific targeting and a higher binding affinity to spiral ganglion neurons, Schwann cells and nerve fibres of the explant cultures were achieved through the ligand mediated multivalent binding to TrkB and p75NTR. Nonspecific uptake of nanoparticles was investigated using nanoparticles conjugated with a scrambled hNgf-EE peptide. The results indicated a selective cochlear cell targeting.

Zhang *et al.*^[65] evaluated the targeting ability of polymersomes to the cochlear nerve by functionalizing the polymersome surface with a tetanin peptide (Tet1) sequence. Tet1 peptide specifically binds to the trisialoganglioside clostridial toxin receptors abundantly present in the cochlear nerve. Tet1 functionalized PEG-*b*-PCL polymersomes were administered using transtympanic injection and cochleostomy. The delivery *via* cochleostomy of Tet1 functionalized polymersomes resulted in a cochlear nerve targeting which in contrast was not seen after transtympanic injection.

Surovtseva *et al.*^[10] evaluated prestin binding ligands to target nanoparticles to the outer hair cells. In biopanning, two 12-mer peptides (A665 and A666) with an affinity to prestin were identified. The binding properties of the A665 and A666 ligands shown by flow cytometry demonstrated a selectivity to prestin expressing Chinese hamster ovary cells. PEG6K-*b*-PCL19K polymersomes covalently labelled with these peptides demonstrated an effective targeting to the outer hair cells of a rat cochlear explant.

Internalization and transfection

Previous efforts have mostly relied upon diffusional, non-targeted methods to deliver the nucleic acid into the cell and nucleus. The use of dynamic chemical processes have provided improved directionality and functionality to carry, for example small interfering RNA (siRNA) and DNA to target cells and into target locations by developing better nanoparticles. Factors that increase internalization include the smaller size of the nanoparticles, a posi-

tive charge, higher nanoparticle concentrations, longer incubation times, higher incubation temperatures and the use of internalization enhancing peptides^[66-69]. The surface charge of the delivery vehicle is an important property of nanoparticles that affects their interaction with cells. A charge promotes cellular uptake but also promotes non-specific interactions with non-target cells and extracellular components such as serum proteins and extracellular matrices^[70].

Clathrin-mediated endocytosis, caveolae-mediated endocytosis and macropinocytosis are the primary internalization pathways of nanoparticles. The pathway by which the carrier enters the cell depends on the carrier type, surface charge, and surface modifications^[67,68,71]. In polymersomes it was demonstrated that the core/corona structure (determined by the composition of the hydrophobic and hydrophilic fractions) affects the internalization pathway, whereas the polymersomes size does not^[72]. Peptide-modified nanoparticles are most likely to be internalized *via* caveolae-mediated endocytosis or macropinocytosis^[71,73,74]. When clathrin and caveolae-mediated endocytotic pathways are inhibited, the internalization *via* the macropinocytosis pathway increases^[67]. The internalization of the block copolymer micelles endocytotic pathways seems to involve pinocytosis, caveolae, clathrin, and caveolae-clathrin independent processes^[75-77].

Soo *et al.*^[78] investigated the endocytic trafficking of silica nanoparticles within the immortalized inner ear cell line (HEI-OC1 cells). They used different sizes of silica nanoparticles of 50, 70 and 100 nm. The 50 nm NPs were the easiest to be internalized and macropinocytosis was the dominant mechanism. During intracellular trafficking, silica nanoparticles were localized in the early endosomes. The trafficking to lysosomes was delayed, however the particles could not escape the endosomes. Similar to these findings is that fluorescent-labelled micelles do not enter the nucleus but can also be found in endosomes/lysosomes, as can most other nanoparticles.

An enhancement of internalization can be achieved through the incorporation of specific ligands to the surface of the nanoparticle. Transferrin has been used as a cell penetrating peptide as most cells have transferrin receptors^[79]. The transferrin targeting ligands theoretically have a disadvantage as transferrin is recycled in the cells and the nanoparticles may be transported outside of the cell. The transcriptional transactivator peptide, tat-peptide, or a modified sequence of the human immunodeficiency virus surface peptide, is commonly used to enhance nanoparticle delivery efficacy. Tat-peptide usage also improves the transfection, *i.e.*, the delivered DNA reaching into, and reading within the nucleus. Internalization peptides are usually covalently bound on the PEG layer. The targeting peptides, internalization and transfection peptides cover about 1%-2% of the surface of the PEGylated nanoparticle^[65,80]. Functionalized nanoparticles offer opportunities to achieve many desired characteristics. Figure 3 shows an example of




Figure 3 Composition of a targeted nanoparticle. MRI: Magnetic resonance imaging.

ideal nanoparticle for inner ear therapy. It contains nerve stimulating growth factor (BDNF)^[61], the *Atoh-1* gene for transformation of supporting cells to outer hair cells^[11], siRNA for removing the inhibition of E-Box of *Atoh-1* gene action^[61], dexamethasone to diminish tissue trauma during surgery^[81], SPION to allow visualization of the nanoparticle payload in MRI^[82], tat-peptide to improve internalization^[83] and TrkB receptor-peptide for targeting^[4,44].

Endosomal escape

Depending on internalization pathways, nanoparticles usually enter the early endosomes, continue to the late endosome and finally are stored and destroyed by lysosomes (Figure 4). A promising method to escape the late endosomes and lysosomes is to create nanoparticles that are chemically dynamic, and are able to cleave the chemical bonds of lysosomes. An example of this approach is the use of endosomal escape mediating proteins that improve the release of nucleic acids from the endosomes, a key step during the transport of genetic material^[76].

Several peptides have been shown to disrupt the endosomal membrane and allow pathogens, therapeutics and plasmids transit to the cytoplasm^[84]. These fusogenic, pH sensitive peptides are mostly derived from bacterial pathogens. This conceptual approach was first

revealed using the cationic peptide melittin and cyclic anhydrides^[85]. Melittin is an extremely cytotoxic, membrane lytic peptide that contains several critical lysine residues. To mask melittin's membrane activity, its lysine epsilon amino groups were reversibly modified using cyclic anhydrides. The key to this strategy is the choice of the labile bond. When the endosomal escape mediating peptides (EEMPs) enter the acidic environment of the endosome, a pH-labile bond is broken, so releasing the agent's endosomolytic capability^[86]. The use of labile bonds to mask membrane activity provides a critical design feature of EEMPs, because it enables efficient *in vivo* delivery without sacrificing endosomolytic function for release into the cytoplasm. The HA2/INF peptide has been used by several researchers^[87-89]. The fusogenic pH sensitive peptide GALA provides a different strategy to combat endosome trapping^[84,90,91]. Some of these peptides form pores in the membrane. Recently, an endosomolytic agent used within dynamic polyconjugates, enabled the efficient delivery of siRNA into hepatocytes *in vivo*^[92]. In gene transfer, *in vitro* luciferase gene expression was increased 1800-fold when melittin was modified with dimethylmaleic anhydride and covalently coupled to poly-L-lysine (PLL), when compared to unmodified PLL^[93].

In liposomes, citraconic anhydride has been used to




Figure 4 Internalization and cellular trafficking of nanoparticles. TrkB: Tyrosine kinase B receptor; BDNF: Brain derived neurotrophic factor; TAT: Tactical arrival time.

reversibly modify the primary amine of dioleoyl phosphatidylethanolamine (DOPE), to form citraconyl-DOPE^[94]. In an acidic environment, the citraconyl group is cleaved reforming DOPE. In nanoparticles, pDNA was complexed with poly-lysine, which was then mixed with negatively charged liposomes containing citraconyl-DOPE, DOPE and DOPE-PEG-folic acid. This ternary complex showed a higher transfection activity than those liposomes containing cholesterol hemisuccinate instead of citraconyl-DOPE^[95]. An extensive review on the use of escape peptides has been provided elsewhere^[93].

Nuclear entry and DNA integrating in the genome

DNA introduced into cells by synthetic carriers is usually trafficked to the cell interior along the endocytic pathway. Once released from the endosomes, the DNA or nanoparticle with DNA must travel through the cytoplasm in order to reach the nuclear envelope. However, the diffusion of large (> 500 kDa) molecules through the molecularly crowded and sterically obstructed environment of the cytoplasm is highly restricted. The results of non-viral gene transfer have shown surprisingly low levels of overall transfection, with $< 1\%$ of the DNA, which is taken up by a cell, ever being expressed^[96,97]. The unique structural properties of DNA further attenuate its diffusion. However, when plasmids with different sizes were injected into the mice tail vein, the efficiency of delivery was independent of the vectors size^[98]. Even if a DNA vector reaches the nuclear envelope it must then translocate across nuclear pore complexes in order to reach its destination^[99]. Nuclear pore

complexes (NPC), which operate as selective conduits for nucleo-cytoplasmic exchange in eukaryotes, support two modes of transport. For non-dividing, differentiated target cells, the nuclear entry is highly dependent on transport *via* NPCs. Particles smaller than 8-9 nm may enter by diffusion, while larger particles are ushered selectively by soluble receptors of the karyopherin/importin β family, which recognise the specific nuclear import signal (NLS) or export signal peptides displayed by the cargo^[100,101]. This mode is used to transport objects below 40 nm in diameter. Given its large hydrodynamic radius and the lack of nuclear targeting signals, DNA is expected to translocate very poorly through nuclear pore complexes. Unless assisted, the translocation of DNA through nuclear pores is limited. Only very short segments, in the order of approximately 100-500 bp can pass the NPC^[100]. Obstruction of these two important cellular processes therefore render transfection efficiencies by synthetic carriers as unacceptably low, particularly in the case of non-dividing cells and localised gene delivery.

Extensive effort has been placed on enhancing the nuclear import of delivered DNA by direct or indirect association with NLS moieties^[100,102]. This effort has largely been in vain, because the size and chemical properties of the DNA dramatically attenuate its transport into the cell cytoplasm and through the nuclear pore complex channel, so resulting in poor nuclear transfer. The use of nano-carrier DNA complexes, functionalized by moieties with nuclear-targeting activity, offers a highly promising means to overcome the nuclear barrier and in-




Figure 5 Example showing nuclear pore complexes targeted Tat-coated nanoparticle containing Math-1 plasmid and PiggyBac transposome. NLS: Nuclear import signal; TAT: Tactical arrival time.

duce the efficient nuclear import of DNA^[103]. To maximize nuclear targeting, various nucleus targeting moieties (NLSs) chosen from aptamer libraries and sulfhydryl-reactive linker molecules, have been utilized^[104]. With the goal of identifying the most efficient NLSs, the nuclear accumulation and kinetics of the nuclear import of various quantum dots-NLS complexes have been used^[105]. Despite present knowledge of the interaction of NLSs with their cellular partners, it remains impossible to predict their effectiveness in nuclear penetration.

This limitation of biological activity is exacerbated by the fact that in most cases, DNA remains epi-chromosomal, so necessitating repeated administrations (Figure 5). Kim *et al.*^[106] reviewed the possible use of transposons to integrate DNA in the genome with nanoparticles. Transposons have proved promising elements for gene integration and the Sleeping Beauty system has been predominant for many years, although there have been several other transposon systems available, for example, Tol2^[107]. Recently however, another system known as PiggyBac has been introduced and developed for fulfilling the same purposes (for example, mutagenesis, transgenesis and gene therapy). In some cases there has been improved transposition efficiency and advantages over the Sleeping Beauty transposon system have been demonstrated. The improved hyperactive transposase

in PiggyBac has increased the transposition efficacy of Sleeping Beauty^[108]. PiggyBac is still to be tested however in the context of different functionalized nanoparticles. A further hindrance in the development of successful gene therapy has been the detrimental response of the immune system. Understanding the sequence of inflammatory responses which occur after PiggyBac delivery, may though enable the identification of points at which immune modulation could dramatically improve the efficacy of gene therapy of the inner ear^[106].

PAYLOAD

Delivering growth factor to non-targeted cells may cause adverse effects. This has been recently well illustrated in the innovative treatment of Parkinson's disease with glial nerve growth factor (GDNF), in that the drug was delivered *via* catheters locally into the CNS. However, the therapy was partly unsuccessful and caused serious adverse effects as the drug could not be sufficiently targeted to specific cells^[109]. This issue may be managed with targeted delivery^[44,65,110].

Nanoparticles loaded with tracers, drug, genes and siRNA have been examined in the context of the inner ear. When compared to pDNA, the much smaller size of the siRNA and a need to achieve only a cytoplasmic




Figure 6 Illustration of the tyrosine kinase B receptor-targeting liposome nanoparticles that express short hairpin RNA to silence inhibitor of differentiation and DNA binding-2 and a reporter enhanced green fluorescent protein. shRNA: Short hairpin RNA; EGFP: Enhanced green fluorescent protein; TrkB: Tyrosine kinase B receptor.

delivery, renders the delivery of siRNA more tractable. McCall *et al.*^[8] review the use of siRNA in silencing dominant mutations of genes. Although RNAi techniques are still in the early stages of development, their potential to dramatically alter human inner ear disease is enormous in nanoparticle based therapy^[4]. RNAi technology seems particularly well-suited for treating dominant-negative forms of hearing loss by reducing the amount of aberrant mRNA available for translation. It has been successfully applied in a mouse model for GJB2-related hearing loss caused by an autosomal dominant nonsyndromic form of hearing loss caused by a dominant-negative mutation^[111]. RNAi has also been used to reduce cisplatin-related hearing loss in a rat model^[112]. Tamura *et al.*^[23] investigated the efficacy of PLGA nanoparticles to deliver therapeutic molecules to the cochlea. After a systemic application of rhodamine labelled nanoparticles, fluorescence was identified in the liver, kidney, and cochlea. A sustained delivery of rhodamine however, only took place in the liver and not in the kidney or cochlea. Rhodamine nanoparticles placed on the RWM were identified in the scala tympani, indicating that PLGA nanoparticles can permeate through the RWM. Furthermore, the local application of rhodamine nanoparticles to the RWM was more effective in targeted delivery to the cochlea than in systemic application. In a successive study, PLGA nanoparticles encapsulating lidocaine were placed on the RWM of guinea pigs, and resulted in reasonable concentrations of lidocaine being seen in the cochlea without serious adverse effects^[110,113]. The authors of the study postulated its use against tinnitus. They also applied insulin-like growth factor-1 in combination with a gelatine hydrogel on the RWM to improve hearing after sudden deafness^[114] and the phase I / II a clinical trial of these experiments has now been commenced.

Gene therapy offers new treatment possibilities for a large number of commonly acquired and inherited human inner ear diseases where conventional therapy has proven ineffective. Effective methods to stimulate new functional hair cell regeneration in the inner ear would be of therapeutic value for treatment of hearing and balance deficits. One potential strategy to regenerate hair

cells is to induce a phenotypic trans-differentiation of the non-sensory cells that reside in the inner ear by using *Math-1* gene, or to remove the inhibition exerted by id-proteins^[45,115].


A TrkB affinity peptide was synthesized and coupled to liposome nanoparticles carrying the plasmid pGene-Clip™ hMGFP encoding shRNA, to transiently silence the inhibitor of differentiation and DNA binding-2 (Id2) along with the reporter EGFP^[45] (Figure 6). Internalization and targetability were analysed in primary cochlear cell culture, cochlear explants, and live rats. There was efficient internalization in primary cochlear cell culture for both peptide-functionalized liposome nanoparticles and blank liposome nanoparticles in a concentration-dependant manner. Both particles showed uptake in the spiral ganglion cells and adjacent nerve fibres in live rats. A more efficient gene expression was seen for the peptide-functionalized liposome nanoparticles, and the function of shRNA was demonstrated in cochlear explants and adult rat cochleae^[45,61]. It was concluded that the functionalization of liposome nanoparticles with a TrkB ligand did not change cellular internalization, but did enhance gene expression.

Zhang *et al.*^[45] studied transduction of the *Math1* gene using nanoparticle based gene delivery. After constructing the pCDNA6.2/C-EmGFP-Math1 expression plasmid, the plasmid was transfected into different cell lines and primary cochlear cells. Liposome nanoparticles containing the *Math1* plasmid expressed the gene with variable efficiencies, depending on the particle size, surface charge and PEGylation status. The unique intracellular trafficking of *Math1* with dynamics from the cytoplasm to the nucleus was demonstrated. The modification of mesenchymal stem cells by *Math1* gene delivery together with BDNF and GDNF treatments can potentially be applied to cell replacement for the treatment of cochlear spiral ganglion cell loss in deafness.

DELIVERY ROUTES OF NANOPARTICLES INTO THE INNER EAR

Therapeutic agents for the treatment of inner ear dis-

Schematic display of human RWM


Figure 7 Human round window membrane and inner ear with different layers. RWM: Round window membrane.

eases are being rapidly developed, although the delivery methods are still undergoing improvement. Nanoparticle based delivery into the inner ear has been investigated using either systemic or local delivery^[11,12,81,116-118]. There are two different approaches to deliver the nanoparticles locally: (1) Through transtympanic delivery (*via* an intact RWM or oval window); and (2) intracochlear delivery^[3,119-121]. Tamura *et al.*^[23] compared PLGA nanoparticles delivered *via* systemic injection, administered either locally onto an intact RWM or injected into the vestibulum of the inner ear. The results indicated that an injection into the vestibulum was the most efficient method, with intact RWM delivery being moderately efficient and systemic delivery exhibiting the least efficiency^[23]. In another study, the systemic delivery of viral vectors resulted in no cochlear gene expression^[122]. The low delivery efficiency and obvious adverse effects render systemic administration as a non-optimal method with which to treat inner ear diseases^[21,22].

A comparison of topical RWM surface delivery, transtympanic injection and cochleostomy provided information regarding the optimization of inner ear drug delivery using polymerosome nanoparticles^[65]. Although transtympanic injection was not superior to topical RWM surface delivery (using a gelatin sponge) of nanoparticles into the cochlea, it was more efficient in delivering nanoparticles into the vestibulum. However, both methods failed to introduce nanoparticles into the spiral ganglion or into Corti's organ *in vivo*. Among the evaluated delivery approaches, cochleostomy is the most promising method with which to deliver polymerosomes

into these locations^[45,65]. For RWM delivery, Zhang *et al.*^[45] concluded the passage of nanoparticles as taking the following steps: polymerosomes were first taken up by the endothelial cells, then diffused into the connective tissue core through the loose intercellular gaps of the endothelium. They were finally internalized by the epithelial cells when they were delivered into the cochlear perilymph. However, most of the polymerosomes were unable to cross the tight junction of the epithelial layer of the RWM when they were administered either *via* topical RWM surface delivery or transtympanic injection (Figure 7). The topical RWM surface administration of gadolinium chelate results in the efficient loading of the contrast agent in the rat inner ear as shown by *in vivo* magnetic resonance imaging (MRI)^[123]. Transtympanic injection of PEGylated liposome nanoparticles encapsulating gadolinium-tetra-azacyclododecane-tetra-acetic acid (Gd-DOTA) passed through the RWM efficiently *in vivo* as determined by the Gd-DOTA MRI signal in the inner ear^[124]. The variable efficacies of different substances in crossing the middle-inner ear barriers may be dependent upon the surface characteristics of the nanostructures.

Permeability of the RWM is influenced by several factors, including the thickness of the membrane and the size, configuration, concentration, liposolubility, and electrical charge of the delivered substance^[125]. The thickness of the RWM is variable depending on the species studied. In mice this thickness is 6-10 μm ^[126], in rats 15 μm ^[127], in chinchillas 10-14 μm ^[125], in guinea pigs 10 μm ^[128], and in humans 70 μm ^[129]. Humans have the thickest RWM, which is thicker at the rim than in the




Figure 8 Porous annular ligament between the stapes footplate and vestibular window. Source: Reference^[141], with permission. VW: Vestibular window; S: Stapes.

central region. The epithelial layer of the RWM has tight junctions^[125], whereas the connective tissue layer and the endothelial layer are loosely arranged. The results showing that polymerosomes were detected only in the epithelial layer of the RWM following topical RWM surface delivery and transtympanic injection, but detected in all three RWM layers when administered through cochleostomy, suggest that the epithelial layer is the flow limiting structure for polymerosomes in their transport from the middle ear to the cochlea^[11]. Nanoparticles, such as liposomes, polymers and polymer-encapsulated SPIONs were shown to cross the RWM^[12,25,130]. However, the penetration efficacy of nanoparticles is not as high as that of viral vectors. The chosen delivery method also influences the passing of substances through the RWM. For example, BDNF administered by a single transtympanic injection or by sustained RWM application in rats resulted in 0.0001% and 0.002% of the original concentration in the perilymph after 3 d, respectively^[131].

PEG-*b*-PCL polymerosomes, LNCs and silica nanoparticles loaded with fluorophores can pass through the RWM and the oval window, and are detected in the cochlea and the vestibulum^[12,13,132]. PEG-PLA and PLGA nanoparticles can deliver drugs to the inner ear *via* either local RWM or systemic application^[81,113]. Contrast agents, such as Gd-DOTA and superparamagnetic iron oxide nanoparticles (SPIONs), encapsulated in liposomes, polymers and copolymers were visualized in the inner ear using MRI, light microscopy and electrical microscopy. The penetration of the SPIONs was enhanced through the use of an external magnetic field^[116,117,133-135].

Several efforts have been made to improve the permeability of the RWM for delivery. For example, a disruption of the RWM epithelial layer was attempted with silver nitrate, trichloroacetic acid and phenol, but these methods did not achieve satisfactory results^[136,137]. A partial digestion of the RWM using a collagenase solution increased the RWM permeability to recombinant adeno-associated virus (rAAV) vectors and enhanced the transfection efficacy^[138]. Cell-penetrating peptides were also used to improve the passage of nanoparticles through

model membranes^[139,140].

Oval window delivery

The oval window (OW) is the barrier between the perilymph in the vestibulum and the middle ear cavity. A histological study in rats demonstrated that the annular ligament across the stapedio-vestibular joint is a porous structure composed of fibrillin, 36-kDa microfibril-associated glycoprotein (MAGP-36), and hyaluronic acid^[141] (Figure 8). The distance from the oval window to the sacculus is 1.66 mm in humans, and the distance to the utricle is 2.25 mm^[142]. *In vivo* MRI studies of guinea pigs, rats, and humans indicate that the oval window is more permeable to gadolinium than the RWM^[134,135,143]. Selective vestibular delivery *via* the oval window pathway was demonstrated in a recent MRI study performed by Zou *et al.*^[118] in which the contrast agent was injected into the epitympanum. This novel method was translated into practice in the ear clinic to treat Meniere's disease, and we have therefore changed our own clinical practice and currently use a 50 μ L injection into the upper posterior tympanic cavity to allow the OW penetration of gentamicin. This seems to be more effective than filling the whole tympanic cavity and so far we have not experienced severe hearing loss (personal information). Therefore, for nanoparticle delivery, the OW provides an alternative pathway especially to the vestibulum and cochlea.

Intracochlear delivery

At present, intracochlear delivery is the most efficient method for gene delivery to the inner ear^[65,120,144]. Although hydrogel-administered BDNF to the topical RWM surface with sustained release was reported to partially protect SGCs from degeneration, an intracochlear application of BDNF resulted in full preservation^[131,145]. During cochlear implantation, protective therapeutic agents such as neurotrophins and dexamethasone, can also be administered with an electrode array^[146,147]. However, intracochlear application of a given substance is not an optimal method except in cochlear implants, as it has the potential to induce deafness and inflammation^[130].

Nanoparticle imaging




Figure 9 Schematic representation of imaging of nanoparticles in the inner ear of guinea pig with magnetic resonance imaging. The cochlear nerve (8n) and cochlear basal turn (basal) are indicated. As nanoparticle transmission electron microscopy of multifunctional poly-lactic-co-glycolic acid -nanoparticle is shown. The star-like dots in the fluid spaces of the cochlea and the cochlear nerve demonstrate the distribution of gadolinium chelate used for visualization. The small dots indicate nanoparticles, their ingredients and dye for histological confirmation of targeting.

Trans-cochlear pathways

In vivo MRI studies on small animals, including guinea pigs, rats, and mice have demonstrated novel routes of gadolinium through the modiolus and lateral wall^[124,134,143,148-150]. Increased evidence for this novel communication route was obtained through combined SEM and light microscopy in the human cochlea, so demonstrating that the modiolar wall of the SV and ST in the first and second turn is porous, forming a perilymphatic communication route to the peri-vascular and peri-neural spaces in the modiolus. A “peri-modiolar lymph” or fluid space can be identified in the modiolar periphery^[151]. The openings on the modiolar wall may be used therapeutically, in that nanoparticles migrate to SGCs from the perilymph of the ST^[135,143,149,151]. Migration can also take place from the ST to the SV *via* either the SL or the modiolus^[123,143,149,152]. When substances enter the perilymph of the ST through the RWM or intracochlearly, they perfuse through fibrocytes of the SL *via* openings in the mesothelial sheet facing the perilymph^[151-155]. A fourth pathway is through Corti’s organ which has a loose structure, and drugs applied to the perilymph of the ST can access nearly all of the cochlear cell populations and the nerve fibres of the peripheral processes of the SGCs^[156]. Lastly, perfusion can also occur between the basal SV and the vestibulum^[152].

IMAGING OF THE NANOPARTICLE *IN VIVO*

Tracking the distribution of nanoparticles within the

inner ear is an important parameter that can be determined with expert imaging tools^[25,123]. In experimental studies, several investigations have been carried out with 4.7 T magnetic resonance imaging (MRI) to evaluate the dynamics of nanoparticles (Figure 9). When injected into the middle ear, the nanoparticles containing contrast agent allow the determination of the dynamic distribution rate of nanomaterial in a living organism. Both SPION nanoparticles and gadolinium chelate containing nanoparticles have been used. The resolution obtained *in vivo* by the system is at best 78 μm × 78 μm × 78 μm. The two contrast agents are complementary to each other and can be applied to human studies to describe accurately the pathway and destiny of the nanoparticles in the inner ear.

Zou *et al.*^[157] developed MRI traceable tracking lipoplexes by encapsulating gadolinium-tetra-azacyclo-dodecane-tetra-acetic acid (LPS + Gd-DOTA) within the liposome nanoparticles. The functionalized nanoparticles could be traced after either intratympanic or intracochlear administration and their distribution in the inner ear could be visualized. LPS + Gd-DOTA with 130 nm size were efficiently taken up by the inner ear 3 h after transtympanic injection and disappeared after 24 h^[118]. With intracochlear injection, LPS + Gd-DOTA were rapidly distributed throughout the inner ear, including the cochlea and vestibule. The transportation efficacy of LPS + Gd-DOTA across the middle-inner ear barriers depends on the size of the liposome^[118]. The disadvantage of using chelated gadolinium is that the concentration of gadolinium must be high enough to be detected:




Figure 10 Magnetic resonance imaging of the inner ear of rat using SPION as contrast agent. The upper figure shows T1 weighted imaging where all cochlear fluid spaces are visible. The lower figure shows T2 weighted image where SPION injected into the perilymphatic space will reduce the T2 signal and the perilymphatic space signal is extinguished. Only the fluid in scala media (endolymph) is visible. Am: Ampulla; Coch: Cochlea; Sa: Saccus; LSCC: Lateral semicircular canal; SSCC: Superior semicircular canal; PSSC: Posterior semicircular canal; SM: Scala media.

when compared for example to using SPION, the detectable amount of gadolinium (Gd) must be 100-500 times greater.

Poe *et al.*^[82] compared SPION with Gd in MRI in the visualization of the inner ear in a rat model (Figure 10). While Gd demonstrated enhancement of the perilymph, SPION attenuates the proton signal in perilymph and in MRI was devoid of a signal, yet the sensitivity of SPION was much greater than Gd. Zou *et al.*^[124] used SPION in the visualization of the cochlear compartments with a 4.7 T MRI scanner. POA@SPION was administered through intracochlear, intratympanic and intravenous routes. It passed through the middle-inner ear barriers in only small amounts, but stayed in the perilymph for 3 d. There was no traverse of the blood-perilymph barrier or blood-endolymph barrier. The inner ear distribution of POA@SPION was confirmed by histology. POA@SPION is a promising T2 negative contrast agent. The authors of the study demonstrated that POA@SPION can be introduced into the perilymph space, after which it becomes widely distributed. As such, SPIONs can be used to demonstrate the integrity of the perilymph-endolymph barrier.

Labelling cells with SPIONs has potential advantages over gadolinium. These are owing to the high spatial resolution of MRI and the fact that SPION labels are non-toxic to the cells since the iron oxide nanoparticles are biodegradable and metabolized by the same cells^[158,159]. SPION labelling of cells may provide researchers with a tool to understand the role or contribution of a specific cell population in normal and abnormal development or in pathological processes. *In vitro* labelling of cells with SPIONs allows for the detection of single labelled cells within target tissues using MRI, following either direct implantation or intravenous injection^[160]. *In vitro* experiments have shown that SPION labelled cells can move towards an external magnetic field and magnetically labelled cells can be delivered and retained at a site of interest by applying an external magnetic field^[160]. The magnetic targeting of genetically altered cells or cells serving as delivery vehicles for genes may be feasible in

the future by infusing SPION labelled cells during angiography or invasive procedures and by placing an external magnet over a predetermined region, using image guidance to maximize the delivery and retention of cells in a target tissue^[158].

It has been suggested that *in vivo* imaging will provide demonstration of biocompatibility, membrane penetration, and targetability of the MFNP within the cochlea. With the development of novel magnetic nanoparticles, MRI has led to wider biomedical applications in “theragnostic” (therapeutic and diagnostic) applications such as in hyperthermia^[161], stem cell tracking^[162], gene expression^[163], cancer detection^[164], and inflammation^[165].

CONCLUSION

Hearing loss is a large burden affecting around 13% of the European population. Novel techniques to downsize drug carriers to nano-sizes and attach them with targeting moieties demonstrate new opportunities for successful drug/gene delivery into the inner ear. Nanoparticle-mediated gene transfer is an attractive methodology because of its simplicity and reduced toxicity, and it holds promise in providing a major break-through for future therapy. In spite of the modest efficacy of gene transfection, several disease models have been successfully modulated by use of the synthetic vector system. To enhance the utility of these vectors it is necessary to increase their packing capacity and the level of gene expression of which they are capable. It is also important to prolong gene expression, as well as to increase their target cell specificity. For protection of hostile DNase from hostile enzymes, PEGylation and covalently attaching targeting moieties, peptides enhancing internalization and peptides that mediate the nuclear localization signal, may provide a solution for a drug delivery system for organs difficult to reach, such as the inner ear.

REFERENCES

- 1 Ruben RJ. Redefining the survival of the fittest: communi-

- cation disorders in the 21st century. *Laryngoscope* 2000; **110**: 241-245 [PMID: 10680923 DOI: 10.1097/00005537-200002010-00010]
- 2 **Gates GA**, Cooper JC. Incidence of hearing decline in the elderly. *Acta Otolaryngol* 1991; **111**: 240-248 [PMID: 2068909]
- 3 **Bowe SN**, Jacob A. Round window perfusion dynamics: implications for intracochlear therapy. *Curr Opin Otolaryngol Head Neck Surg* 2010; **18**: 377-385 [PMID: 20808222 DOI: 10.1097/MOO.0b013e32833d30f0]
- 4 **Pyykkö I**, Zou J, Zhang W, Zhang Y. Nanoparticle-based delivery for the treatment of inner ear disorders. *Curr Opin Otolaryngol Head Neck Surg* 2011; **19**: 388-396 [PMID: 21897248 DOI: 10.1097/MOO.0b013e32834aa3a8]
- 5 **Nakagawa T**, Ito J. Local drug delivery to the inner ear using biodegradable materials. *Ther Deliv* 2011; **2**: 807-814 [PMID: 22822510]
- 6 **Zou J**, Asukas J, Inha T, Toppila E, Kellomäki M, Pyykkö I. Biocompatibility of different biopolymers after being implanted into the rat cochlea. *Otol Neurotol* 2008; **29**: 714-719 [PMID: 18580700 DOI: 10.1097/MAO.0b013e31817d874b]
- 7 **Sun H**, Huang A, Cao S. Current status and prospects of gene therapy for the inner ear. *Hum Gene Ther* 2011; **22**: 1311-1322 [PMID: 21338273 DOI: 10.1089/hum.2010.246]
- 8 **McCall AA**, Swan EE, Borenstein JT, Sewell WF, Kujawa SG, McKenna MJ. Drug delivery for treatment of inner ear disease: current state of knowledge. *Ear Hear* 2010; **31**: 156-165 [PMID: 19952751 DOI: 10.1097/AUD.0b013e3181c351f2]
- 9 **Wang X**, Dellamary L, Fernandez R, Harrop A, Keithley EM, Harris JP, Ye Q, Lichter J, LeBel C, Piu F. Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach. *Audiol Neurotol* 2009; **14**: 393-401 [PMID: 19923809 DOI: 10.1159/000241896]
- 10 **Surovtseva EV**, Johnston AH, Zhang W, Zhang Y, Kim A, Murakoshi M, Wada H, Newman TA, Zou J, Pyykkö I. Prestin binding peptides as ligands for targeted polymer-some mediated drug delivery to outer hair cells in the inner ear. *Int J Pharm* 2012; **424**: 121-127 [PMID: 22227343 DOI: 10.1016/j.ijpharm.2011.12.042]
- 11 **Zhang W**, Zhang Y, Löbler M, Schmitz KP, Ahmad A, Pyykkö I, Zou J. Nuclear entry of hyperbranched polylysine nanoparticles into cochlear cells. *Int J Nanomedicine* 2011; **6**: 535-546 [PMID: 21468356 DOI: 10.2147/IJN.S16973]
- 12 **Zou J**, Saulnier P, Perrier T, Zhang Y, Manninen T, Toppila E, Pyykkö I. Distribution of lipid nanocapsules in different cochlear cell populations after round window membrane permeation. *J Biomed Mater Res B Appl Biomater* 2008; **87**: 10-18 [PMID: 18437698 DOI: 10.1002/jbm.b.31058]
- 13 **Praetorius M**, Brunner C, Lehnert B, Klingmann C, Schmidt H, Staecker H, Schick B. Transsynaptic delivery of nanoparticles to the central auditory nervous system. *Acta Otolaryngol* 2007; **127**: 486-490 [PMID: 17453474 DOI: 10.1080/00016480600895102]
- 14 **Petros RA**, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. *Nat Rev Drug Discov* 2010; **9**: 615-627 [PMID: 20616808]
- 15 **Lamprecht A**, Bouligand Y, Benoit JP. New lipid nanocapsules exhibit sustained release properties for amiodarone. *J Control Release* 2002; **84**: 59-68 [PMID: 12399168]
- 16 **Chiang A**, Haller JA. Vitreoretinal disease in the coming decade. *Curr Opin Ophthalmol* 2010; **21**: 197-202 [PMID: 20224401 DOI: 10.1097/ICU.0b013e32833866db]
- 17 **Dong X**, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. *Nanomedicine (Lond)* 2010; **5**: 597-615 [PMID: 20528455 DOI: 10.2217/nmm.10.35]
- 18 **Tamaki Y**. Prospects for nanomedicine in treating age-related macular degeneration. *Nanomedicine (Lond)* 2009; **4**: 341-352 [PMID: 19331541 DOI: 10.2217/nmm.09.10]
- 19 **Jain JP**, Kumar N. Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation. *Eur J Pharm Sci* 2010; **40**: 456-465 [PMID: 20580669 DOI: 10.1016/j.ejps.2010.05.005]
- 20 **Kreuter J**. Nanoparticulate systems for brain delivery of drugs. *Adv Drug Deliv Rev* 2001; **47**: 65-81 [PMID: 11251246 DOI: 10.1016/j.addr.2012.09.015]
- 21 **Hoarau D**, Delmas P, David S, Roux E, Leroux JC. Novel long-circulating lipid nanocapsules. *Pharm Res* 2004; **21**: 1783-1789 [PMID: 15553223]
- 22 **Robey AB**, Morrow T, Moore GF. Systemic side effects of transtympanic steroids. *Laryngoscope* 2010; **120** Suppl 4: S217 [PMID: 21225815 DOI: 10.1002/lary.21684]
- 23 **Tamura T**, Kita T, Nakagawa T, Endo T, Kim TS, Ishihara T, Mizushima Y, Higaki M, Ito J. Drug delivery to the cochlea using PLGA nanoparticles. *Laryngoscope* 2005; **115**: 2000-2005 [PMID: 16319613 DOI: 10.1097/01.mlg.0000180174.81036.5a]
- 24 **Zhang Y**, Zhang W, Löbler M, Schmitz KP, Saulnier P, Perrier T, Pyykkö I, Zou J. Inner ear biocompatibility of lipid nanocapsules after round window membrane application. *Int J Pharm* 2011; **404**: 211-219 [PMID: 21075187 DOI: 10.1016/j.ijpharm.2010.11.006]
- 25 **Pyykkö I**, Zou J, Poe D, Nakashima T, Naganawa S. Magnetic resonance imaging of the inner ear in Meniere's disease. *Otolaryngol Clin North Am* 2010; **43**: 1059-1080 [PMID: 20713245 DOI: 10.1016/j.otc.2010.06.001]
- 26 **Zhang L**, Granick S. How to stabilize phospholipid liposomes (using nanoparticles). *Nano Lett* 2006; **6**: 694-698 [PMID: 16608266 DOI: 10.1021/nl052455y]
- 27 **Ranjan S**, Sood R, Dudas J, Glueckert R, Schrott-Fischer A, Roy S, Pyykkö I, Kinnunen PK. Peptide-mediated targeting of liposomes to TrkB receptor-expressing cells. *Int J Nanomedicine* 2012; **7**: 3475-3485 [PMID: 22848172 DOI: 10.2147/IJN.S32367ijn-7-3475]
- 28 **Mamaeva V**, Sahlgren C, Lindén M. Mesoporous silica nanoparticles in medicine--recent advances. *Adv Drug Deliv Rev* 2013; **65**: 689-702 [PMID: 22921598 DOI: 10.1016/j.addr.2012.07.018]
- 29 **Lee JC**, Bermudez H, Discher BM, Sheehan MA, Won YY, Bates FS, Discher DE. Preparation, stability, and in vitro performance of vesicles made with diblock copolymers. *Biotechnol Bioeng* 2001; **73**: 135-145 [PMID: 11255161 DOI: 10.1002/bit.1045]
- 30 **Zheng C**, Qiu L, Yao X, Zhu K. Novel micelles from graft polyphosphazenes as potential anti-cancer drug delivery systems: drug encapsulation and in vitro evaluation. *Int J Pharm* 2009; **373**: 133-140 [PMID: 19429298 DOI: 10.1016/j.ijpharm.2009.01.025]
- 31 **Jain JP**, Kumar N. Self assembly of amphiphilic (PEG)(3)-PLA copolymer as polymersomes: preparation, characterization, and their evaluation as drug carrier. *Biomacromolecules* 2010; **11**: 1027-1035 [PMID: 20178378 DOI: 10.1021/bm1000026]
- 32 **Chiruvolu S**, Walker S, Israelachvili J, Schmitt FJ, Leckband D, Zasadzinski JA. Higher order self-assembly of vesicles by site-specific binding. *Science* 1994; **264**: 1753-1756 [PMID: 8209255]
- 33 **Discher BM**, Won YY, Ege DS, Lee JC, Bates FS, Discher DE, Hammer DA. Polymersomes: tough vesicles made from diblock copolymers. *Science* 1999; **284**: 1143-1146 [PMID: 10325219]
- 34 **Li S**, Byrne B, Welsh J, Palmer AF. Self-assembled poly(butadiene)-b-poly(ethylene oxide) polymersomes as paclitaxel carriers. *Biotechnol Prog* 2007; **23**: 278-285 [PMID: 17269699 DOI: 10.1021/bp060208]
- 35 **Cornelissen JJLM**, Fischer M, Sommerdijk NAJM, Nolte RJM. Helical superstructures from charged Poly(styrene)-Poly(isocyanodipeptide) block copolymers *Science* 1998; **280**: 1427-1430 [PMID: 9603730]
- 36 **Jain S**, Bates FS. On the origins of morphological complexity in block copolymer surfactants. *Science* 2003; **300**: 460-464 [PMID: 12553223]

- 12702869 DOI: 10.1126/science.1082193300/5618/460]
- 37 **Niu D**, Ma Z, Li Y, Shi J. Synthesis of core-shell structured dual-mesoporous silica spheres with tunable pore size and controllable shell thickness. *J Am Chem Soc* 2010; **132**: 15144-15147 [PMID: 20939576 DOI: 10.1021/ja1070653]
- 38 **Ahmed F**, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. *J Control Release* 2004; **96**: 37-53 [PMID: 15063028 DOI: 10.1016/j.jconrel.2003.12.021S0168365903006084]
- 39 **Ghoroghchian PP**, Li G, Levine DH, Davis KP, Bates FS, Hammer DA, Therien MJ. Bioresorbable Vesicles Formed through Spontaneous Self-Assembly of Amphiphilic Poly (ethylene oxide) -block-polycaprolactone. *Macromolecules* 2006; **39**: 1673-1675 [PMID: 20975926 DOI: 10.1021/ma0519009]
- 40 **Liu G**, Ma S, Li S, Cheng R, Meng F, Liu H, Zhong Z. The highly efficient delivery of exogenous proteins into cells mediated by biodegradable chimaeric polymersomes. *Biomaterials* 2010; **31**: 7575-7585 [PMID: 20599266 DOI: 10.1016/j.biomaterials.2010.06.021]
- 41 **Wei X**, Zhang Z, Qian Z. Pharmacokinetics and in vivo fate of drug loaded chitosan nanoparticles. *Curr Drug Metab* 2012; **13**: 364-371 [PMID: 22443533 DOI: CDM-EPUB-20120326-003]
- 42 **Paleos CM**, Tsiourvas D, Sideratou Z. Preparation of multi-compartment lipid-based systems based on vesicle interactions. *Langmuir* 2012; **28**: 2337-2346 [PMID: 21988476 DOI: 10.1021/la2027187]
- 43 **Huynh NT**, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. *Int J Pharm* 2009; **379**: 201-209 [PMID: 19409468 DOI: S0378-5173(09)00248-8]
- 44 **Roy S**, Glueckert R, Johnston AH, Perrier T, Bitsche M, Newman TA, Saulnier P, Schrott-Fischer A. Strategies for drug delivery to the human inner ear by multifunctional nanoparticles. *Nanomedicine (Lond)* 2012; **7**: 55-63 [PMID: 22106854 DOI: 10.2217/nnm.11.84]
- 45 **Zhang W**, Zhang Y, Sood R, Ranjan S, Surovtseva E, Ahmad A, Kinnunen PK, Pyrykkö I, Zou J. Visualization of intracellular trafficking of Math1 protein in different cell types with a newly-constructed nonviral gene delivery plasmid. *J Gene Med* 2011; **13**: 134-144 [PMID: 21308898 DOI: 10.1002/jgm.1537]
- 46 **Amoozgar Z**, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. *Wiley Interdiscip Rev Nanomed Nanobiotechnol* 2012; **4**: 219-233 [PMID: 22231928 DOI: 10.1002/wnan.1157]
- 47 **Groll J**, Ameringer T, Spatz JP, Moeller M. Ultrathin coatings from isocyanate-terminated star PEG prepolymers: layer formation and characterization. *Langmuir* 2005; **21**: 1991-1999 [PMID: 15723500 DOI: 10.1021/la047439f]
- 48 **Lutolf MP**, Hubbell JA. Synthesis and physicochemical characterization of end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michael-type addition. *Biomacromolecules* 2003; **4**: 713-722 [PMID: 12741789 DOI: 10.1021/bm025744e]
- 49 **Gombotz WR**, Wang GH, Horbett TA, Hoffman AS. Protein adsorption to poly(ethylene oxide) surfaces. *J Biomed Mater Res* 1991; **25**: 1547-1562 [PMID: 1839026 DOI: 10.1002/jbm.820251211]
- 50 **Stolnik S**, Daudali B, Arien A, Whetstone J, Heald CR, Garnett MC, Davis SS, Illum L. The effect of surface coverage and conformation of poly (ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. *Biochim Biophys Acta* 2001; **1514**: 261-279 [PMID: 11557026]
- 51 **Moghimi SM**, Andersen AJ, Hashemi SH, Lettiero B, Ahmadvand D, Hunter AC, Andresen TL, Hamad I, Szebeni J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. *J Control Release* 2010; **146**: 175-181 [PMID: 20388529 DOI: S0168-3659(10)00257-9]
- 52 **Shimizu T**, Ichihara M, Yoshioka Y, Ishida T, Nakagawa S, Kiwada H. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. *Biol Pharm Bull* 2012; **35**: 1336-1342 [PMID: 22863934 DOI: DN/JST.JSTAGE/bpb/b12-00276]
- 53 **Ishida T**, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. *J Control Release* 2007; **122**: 349-355 [PMID: 17610982 DOI: S0168-3659(07)00242-8]
- 54 **Szebeni J**, Alving CR, Rosivall L, Bünger R, Baranyi L, Bedöcs P, Tóth M, Barenholz Y. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. *J Liposome Res* 2007; **17**: 107-117 [PMID: 17613700 DOI: 779950801]
- 55 **Manil L**, Roblot-Treupel L, Couvreur P. Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. *Biomaterials* 1986; **7**: 212-216 [PMID: 2424511]
- 56 **Vivès E**, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. *J Biol Chem* 1997; **272**: 16010-16017 [PMID: 9188504]
- 57 **Zhang Y**, Schlachetzki F, Zhang YF, Boado RJ, Pardridge WM. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. *Hum Gene Ther* 2004; **15**: 339-350 [PMID: 15053859 DOI: 10.1089/104303404322959498]
- 58 **Kreuter J**, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). *Brain Res* 1995; **674**: 171-174 [PMID: 7773690]
- 59 **Silhol M**, Tyagi M, Giacca M, Lebleu B, Vivès E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. *Eur J Biochem* 2002; **269**: 494-501 [PMID: 11856307]
- 60 **Bitsche M**, Dudas J, Roy S, Potrusil T, Schmutzhard J, Schrott-Fischer A. Neurotrophic receptors as potential therapy targets in postnatal development, in adult, and in hearing loss-affected inner ear. *Otol Neurotol* 2011; **32**: 761-773 [PMID: 21646930 DOI: 10.1097/MAO.0b013e31821f7cc1]
- 61 **Zou J**, Zhang Y, Zhang W, Ranjan S, Sood R, Mikhailov A, Kinnunen P, Pyrykkö I. Internalization of liposome nanoparticles functionalized with TrkB ligand in rat cochlear cell population. *Eur J Nanomedicine* 2008; **3**: 8-14 [DOI: 10.3884/0003.3]
- 62 **Zou J**, Zhang Y, Yin S, Wu H, Pyrykkö I. Mitochondrial dysfunction disrupts trafficking of Kir4.1 in spiral ganglion satellite cells. *J Neurosci Res* 2009; **87**: 141-149 [PMID: 18752300 DOI: 10.1002/jnr.21842]
- 63 **Keisala T**, Minasyan A, Lou YR, Zou J, Kalueff AV, Pyrykkö I, Tuohimaa P. Premature aging in vitamin D receptor mutant mice. *J Steroid Biochem Mol Biol* 2009; **115**: 91-97 [PMID: 19500727 DOI: 10.1016/j.jsbmb.2009.03.007]
- 64 **Minasyan A**, Keisala T, Zou J, Zhang Y, Toppila E, Syväälä H, Lou YR, Kalueff AV, Pyrykkö I, Tuohimaa P. Vestibular dysfunction in vitamin D receptor mutant mice. *J Steroid Biochem Mol Biol* 2009; **114**: 161-166 [PMID: 19429446 DOI: 10.1016/j.jsbmb.2009.01.020]
- 65 **Zhang Y**, Zhang W, Johnston AH, Newman TA, Pyrykkö I, Zou J. Targeted delivery of Tet1 peptide functionalized polymersomes to the rat cochlear nerve. *Int J Nanomedicine* 2012; **7**: 1015-1022 [PMID: 22403485 DOI: 10.2147/IJN.S28185jn-7-1015]
- 66 **Desai MP**, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharm Res* 1996; **13**: 1838-1845 [PMID: 8987081]
- 67 **Harush-Frenkel O**, Debotton N, Benita S, Altschuler Y.

- Targeting of nanoparticles to the clathrin-mediated endocytic pathway. *Biochem Biophys Res Commun* 2007; **353**: 26-32 [PMID: 17184736 DOI: 10.1016/j.bbrc.2006.11.135]
- 68 **Jiang X**, Musyanovych A, Röcker C, Landfester K, Mailänder V, Nienhaus GU. Specific effects of surface carboxyl groups on anionic polystyrene particles in their interactions with mesenchymal stem cells. *Nanoscale* 2011; **3**: 2028-2035 [PMID: 21409242 DOI: 10.1039/c0nr00944j]
- 69 **Panyam J**, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. *FASEB J* 2002; **16**: 1217-1226 [PMID: 12153989 DOI: 10.1096/fj.02-0088com16/10/1217]
- 70 **Ekkapongpisit M**, Giovia A, Follo C, Caputo G, Isidoro C. Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: effects of size and surface charge groups. *Int J Nanomedicine* 2012; **7**: 4147-4158 [PMID: 22904626 DOI: 10.2147/IJN.S33803ijn-7-4147]
- 71 **Wadia JS**, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat Med* 2004; **10**: 310-315 [PMID: 14770178 DOI: 10.1038/nm996nm996]
- 72 **Mahmud A**, Lavasanifar A. The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells. *Colloids Surf B Biointerfaces* 2005; **45**: 82-89 [PMID: 16144761 DOI: 10.1016/j.colsurfb.2005.07.008]
- 73 **del Pozo-Rodríguez A**, Pujals S, Delgado D, Solinís MA, Gascón AR, Giralt E, Pedraz JL. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. *J Control Release* 2009; **133**: 52-59 [PMID: 18854203 DOI: 10.1016/j.jconrel.2008.09.004]
- 74 **Oba M**, Aoyagi K, Miyata K, Matsumoto Y, Itaka K, Nishiyama N, Yamasaki Y, Koyama H, Kataoka K. Polyplex micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking. *Mol Pharm* 2008; **5**: 1080-1092 [PMID: 19434856 DOI: 10.1021/mp800070s]
- 75 **Mukherjee S**, Ghosh RN, Maxfield FR. Endocytosis. *Physiol Rev* 1997; **77**: 759-803 [PMID: 9234965]
- 76 **Medina-Kauwe LK**, Xie J, Hamm-Alvarez S. Intracellular trafficking of nonviral vectors. *Gene Ther* 2005; **12**: 1734-1751 [PMID: 16079885 DOI: 10.1038/sj.gt.3302592]
- 77 **Rapoport N**, Marin A, Luo Y, Prestwich GD, Muniruzzaman MD. Intracellular uptake and trafficking of Pluronic micelles in drug-sensitive and MDR cells: effect on the intracellular drug localization. *J Pharm Sci* 2002; **91**: 157-170 [PMID: 11782905 DOI: 10.1002/jps.10006]
- 78 **Soo PL**, Sidorov SN, Mui J, Bronstein LM, Vali H, Eisenberg A, Maysinger D. Gold-labeled block copolymer micelles reveal gold aggregates at multiple subcellular sites. *Langmuir* 2007; **23**: 4830-4836 [PMID: 17391054 DOI: 10.1021/la063375s]
- 79 **Kolhatkar R**, Lote A, Khambati H. Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors. *Curr Drug Discov Technol* 2011; **8**: 197-206 [PMID: 21696360]
- 80 **Bartneck M**, Keul HA, Wambach M, Bornemann J, Gbureck U, Chatain N, Neuss S, Tacke F, Groll J, Zwadlo-Klarwasser G. Effects of nanoparticle surface-coupled peptides, functional endgroups, and charge on intracellular distribution and functionality of human primary reticuloendothelial cells. *Nanomedicine* 2012; **8**: 1282-1292 [PMID: 22406188]
- 81 **Horie RT**, Sakamoto T, Nakagawa T, Ishihara T, Higaki M, Ito J. Stealth-nanoparticle strategy for enhancing the efficacy of steroids in mice with noise-induced hearing loss. *Nanomedicine (Lond)* 2010; **5**: 1331-1340 [PMID: 21128717 DOI: 10.2217/nnm.10.88]
- 82 **Poe D**, Zou J, Zhang W, Qin J, Abo Ramadan U, Fornara A, Muhammed M, Pyykkö I. MRI of the Cochlea with Superparamagnetic Iron Oxide Nanoparticles Compared to Gadolinium Chelate Contrast Agents in a Rat Model. *Eur J Nanomedicine* 2009; **2**: 29-36 [DOI: 10.3884/0002.2.7]
- 83 **Ye SF**, Tian MM, Wang TX, Ren L, Wang D, Shen LH, Shang T. Synergistic effects of cell-penetrating peptide Tat and fusogenic peptide HA2-enhanced cellular internalization and gene transduction of organosilica nanoparticles. *Nanomedicine* 2012; **8**: 833-841 [PMID: 22033082 DOI: 10.1016/j.nano.2011.10.003]
- 84 **Martin ME**, Rice KG. Peptide-guided gene delivery. *AAPS J* 2007; **9**: E18-E29 [PMID: 17408236 DOI: 10.1208/aaps-j0901003]
- 85 **Rozema DB**, Ekena K, Lewis DL, Loomis AG, Wolff JA. Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules. *Bioconjug Chem* 2003; **14**: 51-57 [PMID: 12526692 DOI: 10.1021/bc0255945]
- 86 **Parente RA**, Nir S, Szoka FC. pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide. *J Biol Chem* 1988; **263**: 4724-4730 [PMID: 2450874]
- 87 **Plank C**, Oberhauser B, Mechtler K, Koch C, Wagner E. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. *J Biol Chem* 1994; **269**: 12918-12924 [PMID: 8175709]
- 88 **Vaysse L**, Burgelin I, Merlio JP, Arveiler B. Improved transfection using epithelial cell line-selected ligands and fusogenic peptides. *Biochim Biophys Acta* 2000; **1475**: 369-376 [PMID: 10913838]
- 89 **Esbjörner EK**, Oglecka K, Lincoln P, Gräslund A, Nordén B. Membrane binding of pH-sensitive influenza fusion peptides. positioning, configuration, and induced leakage in a lipid vesicle model. *Biochemistry* 2007; **46**: 13490-13504 [PMID: 17973492 DOI: 10.1021/bi701075y]
- 90 **Subbarao NK**, Parente RA, Szoka FC, Nadasdi L, Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. *Biochemistry* 1987; **26**: 2964-2972 [PMID: 2886149]
- 91 **Li W**, Nicol F, Szoka FC. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. *Adv Drug Deliv Rev* 2004; **56**: 967-985 [PMID: 15066755 DOI: 10.1016/j.addr.2003.10.041S0169409X03002801]
- 92 **Wolff JA**, Rozema DB. Breaking the bonds: non-viral vectors become chemically dynamic. *Mol Ther* 2008; **16**: 8-15 [PMID: 17955026 DOI: 10.1038/sj.mt.6300326]
- 93 **Meyer M**, Zintchenko A, Ogris M, Wagner E. A dimethylmaleic acid-melittin-polylysine conjugate with reduced toxicity, pH-triggered endosomolytic activity and enhanced gene transfer potential. *J Gene Med* 2007; **9**: 797-805 [PMID: 17628028 DOI: 10.1002/jgm.1075]
- 94 **Drummond DC**, Daleke DL. Synthesis and characterization of N-acylated, pH-sensitive 'caged' aminophospholipids. *Chem Phys Lipids* 1995; **75**: 27-41 [PMID: 7697781 DOI: 10.1016/0009-3084(94)02398-O]
- 95 **Reddy JA**, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. *J Control Release* 2000; **64**: 27-37 [PMID: 10640643]
- 96 **Flotte TR**, Laube BL. Gene therapy in cystic fibrosis. *Chest* 2001; **120**: 124S-131S [PMID: 11555567]
- 97 **Rosenecker J**, Huth S, Rudolph C. Gene therapy for cystic fibrosis lung disease: current status and future perspectives. *Curr Opin Mol Ther* 2006; **8**: 439-445 [PMID: 17078386]
- 98 **Hibbitt OC**, Harbottle RP, Waddington SN, Bursill CA, Coutelle C, Channon KM, Wade-Martins R. Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. *J Gene Med* 2007; **9**: 488-497 [PMID: 17471590 DOI: 10.1002/jgm.1041]
- 99 **Kobiler O**, Drayman N, Butin-Israeli V, Oppenheim A. Virus strategies for passing the nuclear envelope barrier. *Nucleus* 2012; **3**: 526-539 [PMID: 22929056]

- 100 **Ding Q**, Zhao L, Guo H, Zheng AC. The nucleocytoplasmic transport of viral proteins. *Viral Sin* 2010; **25**: 79-85 [PMID: 20960304 DOI: 10.1007/s12250-010-3099-z]
- 101 **Hoelz A**, Debler EW, Blobel G. The structure of the nuclear pore complex. *Annu Rev Biochem* 2011; **80**: 613-643 [PMID: 21495847 DOI: 10.1146/annurev-biochem-060109-151030]
- 102 **Lott K**, Cingolani G. The importin β binding domain as a master regulator of nucleocytoplasmic transport. *Biochim Biophys Acta* 2011; **1813**: 1578-1592 [PMID: 21029753 DOI: 10.1016/j.bbamcr.2010.10.012]
- 103 **Lott K**, Bhardwaj A, Sims PJ, Cingolani G. A minimal nuclear localization signal (NLS) in human phospholipid scramblase 4 that binds only the minor NLS-binding site of importin α 1. *J Biol Chem* 2011; **286**: 28160-28169 [PMID: 21690087 DOI: 10.1074/jbc.M111.228007]
- 104 **Lange A**, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization signals: definition, function, and interaction with importin α . *J Biol Chem* 2007; **282**: 5101-5105 [PMID: 17170104 DOI: 10.1074/jbc.R600026200]
- 105 **Yu J**, Xie X, Zheng M, Yu L, Zhang L, Zhao J, Jiang D, Che X. Fabrication and characterization of nuclear localization signal-conjugated glycol chitosan micelles for improving the nuclear delivery of doxorubicin. *Int J Nanomedicine* 2012; **7**: 5079-5090 [PMID: 23049255 DOI: 10.2147/IJN.S36150ijn-7-5079]
- 106 **Kim A**, Pyrykkö I. Size matters: versatile use of PiggyBac transposons as a genetic manipulation tool. *Mol Cell Biochem* 2011; **354**: 301-309 [PMID: 21516337 DOI: 10.1007/s11010-011-0832-3]
- 107 **Di Matteo M**, Belay E, Chuah MK, Vandendriessche T. Recent developments in transposon-mediated gene therapy. *Expert Opin Biol Ther* 2012; **12**: 841-858 [PMID: 22679910 DOI: 10.1517/14712598.2012.684875]
- 108 **Di Matteo M**, Mátrai J, Belay E, Firdissa T, Vandendriessche T, Chuah MK. PiggyBac toolbox. *Methods Mol Biol* 2012; **859**: 241-254 [PMID: 22367876 DOI: 10.1007/978-1-61779-603-6_14]
- 109 **Slevin JT**, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, Young AB. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. *J Neurosurg* 2007; **106**: 614-620 [PMID: 17432712 DOI: 10.3171/jns.2007.106.4.614]
- 110 **Sakamoto T**, Nakagawa T, Horie RT, Hiraumi H, Yamamoto N, Kikkawa YS, Ito J. Inner ear drug delivery system from the clinical point of view. *Acta Otolaryngol Suppl* 2010; **(563)**: 101-104 [PMID: 20879828 DOI: 10.3109/00016489.2010.486801]
- 111 **Maeda Y**, Fukushima K, Nishizaki K, Smith RJ. In vitro and in vivo suppression of GJB2 expression by RNA interference. *Hum Mol Genet* 2005; **14**: 1641-1650 [PMID: 15857852 DOI: 10.1093/hmg/ddi172]
- 112 **Mukherjee D**, Jajoo S, Whitworth C, Bunch JR, Turner JG, Rybak LP, Ramkumar V. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. *J Neurosci* 2008; **28**: 13056-13065 [PMID: 19052196 DOI: 10.1523/JNEUROSCI.1307-08.2008]
- 113 **Horie RT**, Sakamoto T, Nakagawa T, Tabata Y, Okamura N, Tomiyama N, Tachibana M, Ito J. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles. *Laryngoscope* 2010; **120**: 377-383 [PMID: 19950377 DOI: 10.1002/lary.20713]
- 114 **Nakagawa T**, Sakamoto T, Hiraumi H, Kikkawa YS, Yamamoto N, Hamaguchi K, Ono K, Yamamoto M, Tabata Y, Teramukai S, Tanaka S, Tada H, Onodera R, Yonezawa A, Inui K, Ito J. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. *BMC Med* 2010; **8**: 76 [PMID: 21108784]
- 115 **Izumikawa M**, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF, Brough DE, Raphael Y. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. *Nat Med* 2005; **11**: 271-276 [PMID: 15711559 DOI: 10.1038/nm1193]
- 116 **Kopke RD**, Wassel RA, Mondalek F, Grady B, Chen K, Liu J, Gibson D, Dormer KJ. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. *Audiol Neurotol* 2006; **11**: 123-133 [PMID: 16439835 DOI: 10.1159/000090685]
- 117 **Thaler M**, Roy S, Fornara A, Bitsche M, Qin J, Muhammed M, Salvenmoser W, Rieger G, Fischer AS, Glueckert R. Visualization and analysis of superparamagnetic iron oxide nanoparticles in the inner ear by light microscopy and energy filtered TEM. *Nanomedicine* 2011; **7**: 360-369 [PMID: 21146633 DOI: 10.1016/j.nano.2010.11.005]
- 118 **Zou J**, Sood R, Ranjan S, Poe D, Ramadan UA, Pyrykkö I, Kinnunen PK. Size-dependent passage of liposome nanocarriers with preserved posttransport integrity across the middle-inner ear barriers in rats. *Otol Neurotol* 2012; **33**: 666-673 [PMID: 22569149 DOI: 10.1097/MAO.0b013e318254590e]
- 119 **Schlecker C**, Praetorius M, Brough DE, Presler RG, Hsu C, Plinkert PK, Staeker H. Selective atonal gene delivery improves balance function in a mouse model of vestibular disease. *Gene Ther* 2011; **18**: 884-890 [PMID: 21472006 DOI: 10.1038/gt.2011.33gt201133]
- 120 **Staeker H**, Praetorius M, Brough DE. Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research. *Hear Res* 2011; **276**: 44-51 [PMID: 21251965 DOI: 10.1016/j.heares.2011.01.006]
- 121 **Swan EE**, Mescher MJ, Sewell WF, Tao SL, Borenstein JT. Inner ear drug delivery for auditory applications. *Adv Drug Deliv Rev* 2008; **60**: 1583-1599 [PMID: 18848590 DOI: 10.1016/j.addr.2008.08.001]
- 122 **Stöver T**, Yagi M, Raphael Y. Transduction of the contralateral ear after adenovirus-mediated cochlear gene transfer. *Gene Ther* 2000; **7**: 377-383 [PMID: 10694819 DOI: 10.1038/sj.gt.3301108]
- 123 **Zou J**, Ramadan UA, Pyrykkö I. Gadolinium uptake in the rat inner ear perilymph evaluated with 4.7 T MRI: a comparison between transtympanic injection and gelatin sponge-based diffusion through the round window membrane. *Otol Neurotol* 2010; **31**: 637-641 [PMID: 20142794 DOI: 10.1097/MAO.0b013e3181d2f095]
- 124 **Zou J**, Zhang W, Poe D, Qin J, Fornara A, Zhang Y, Ramadan UA, Muhammed M, Pyrykkö I. MRI manifestation of novel superparamagnetic iron oxide nanoparticles in the rat inner ear. *Nanomedicine (Lond)* 2010; **5**: 739-754 [PMID: 20662645 DOI: 10.2217/nmm.10.45]
- 125 **Goycoolea MV**, Lundman L. Round window membrane. Structure function and permeability: a review. *Microsc Res Tech* 1997; **36**: 201-211 [PMID: 9080410 DOI: 10.1002/(SICI)1097-0029(19970201)36:]
- 126 **Kitamura Y**, Teranishi Ma, Sone M, Nakashima T. Round window membrane in young and aged C57BL/6 mice. *Hear Res* 2002; **174**: 142-148 [PMID: 12433405]
- 127 **Hellström S**, Johansson U, Anniko M. Structure of the round window membrane. *Acta Otolaryngol Suppl* 1989; **457**: 33-42 [PMID: 2929336]
- 128 **Saber A**, Laurell G, Bramer T, Edsman K, Engmér C, Ulfendahl M. Middle ear application of a sodium hyaluronate gel loaded with neomycin in a Guinea pig model. *Ear Hear* 2009; **30**: 81-89 [PMID: 19125030 DOI: 10.1097/AUD.0b013e31818ff98e00003446-200901000-00010]
- 129 **Carpenter AM**, Muchow D, Goycoolea MV. Ultrastructural studies of the human round window membrane. *Arch Otolaryngol Head Neck Surg* 1989; **115**: 585-590 [PMID: 2706104]
- 130 **Jero J**, Mhatre AN, Tseng CJ, Stern RE, Coling DE, Goldstein JA, Hong K, Zheng WW, Hoque AT, Lalwani AK. Cochlear

- gene delivery through an intact round window membrane in mouse. *Hum Gene Ther* 2001; **12**: 539-548 [PMID: 11268286 DOI: 10.1089/104303401300042465]
- 131 **Endo T**, Nakagawa T, Kita T, Iguchi F, Kim TS, Tamura T, Iwai K, Tabata Y, Ito J. Novel strategy for treatment of inner ears using a biodegradable gel. *Laryngoscope* 2005; **115**: 2016-2020 [PMID: 16319616 DOI: 10.1097/01.mlg.0000183020.32435.59]
 - 132 **Zhang Y**, Zhang W, Johnston AH, Newman TA, Pyykkö I, Zou J. Improving the visualization of fluorescently tagged nanoparticles and fluorophore-labeled molecular probes by treatment with CuSO₄ to quench autofluorescence in the rat inner ear. *Hear Res* 2010; **269**: 1-11 [PMID: 20659540 DOI: 10.1016/j.heares.2010.07.006]
 - 133 **Ge X**, Jackson RL, Liu J, Harper EA, Hoffer ME, Wassel RA, Dormer KJ, Kopke RD, Balough BJ. Distribution of PLGA nanoparticles in chinchilla cochleae. *Otolaryngol Head Neck Surg* 2007; **137**: 619-623 [PMID: 17903580]
 - 134 **Zou J**, Yoshida T, Ramadan UA, Pyykkö I. Dynamic enhancement of the rat inner ear after ultra-small-volume administration of Gd-DOTA to the medial wall of the middle ear cavity. *ORL J Otorhinolaryngol Relat Spec* 2011; **73**: 275-281 [PMID: 21876363 DOI: 10.1159/000329760000329760]
 - 135 **Zou J**, Zhang W, Poe D, Zhang Y, Ramadan UA, Pyykkö I. Differential passage of gadolinium through the mouse inner ear barriers evaluated with 4.7T MRI. *Hear Res* 2010; **259**: 36-43 [PMID: 19818391 DOI: 10.1016/j.heares.2009.09.015]
 - 136 **Aarnisalo AA**, Aarnisalo P, Pietola L, Wahlfors J, Jero J. Efficacy of gene transfer through the round window membrane: an in vitro model. *ORL J Otorhinolaryngol Relat Spec* 2006; **68**: 220-227 [PMID: 16549937 DOI: 92123 [pii]10.1159/000092123]
 - 137 **Suzuki M**, Yamasoba T, Suzukawa K, Kaga K. Adenoviral vector gene delivery via the round window membrane in guinea pigs. *Neuroreport* 2003; **14**: 1951-1955 [PMID: 14561927 DOI: 10.1097/01.wnr.0000090584.35425.66]
 - 138 **Wang H**, Murphy R, Taaffe D, Yin S, Xia L, Hauswirth WW, Bance M, Robertson GS, Wang J. Efficient cochlear gene transfection in guinea-pigs with adeno-associated viral vectors by partial digestion of round window membrane. *Gene Ther* 2012; **19**: 255-263 [PMID: 21697953 DOI: 10.1038/gt.2011.91gt201191]
 - 139 **Lindgren ME**, Hällbrink MM, Elmquist AM, Langel U. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. *Biochem J* 2004; **377**: 69-76 [PMID: 12968950 DOI: 10.1042/BJ20030760BJ20030760]
 - 140 **Torchilin VP**. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. *Adv Drug Deliv Rev* 2008; **60**: 548-558 [PMID: 18053612 DOI: 10.1016/j.addr.2007.10.008]
 - 141 **Ohashi M**, Ide S, Kimitsuki T, Komune S, Suganuma T. Three-dimensional regular arrangement of the annular ligament of the rat stapediovestibular joint. *Hear Res* 2006; **213**: 11-16 [PMID: 16476532 DOI: 10.1016/j.heares.2005.11.007]
 - 142 **Takahashi H**, Sando I. Three-dimensional surgical anatomy for stapes surgery computer-aided reconstruction and measurement. *Laryngoscope* 1992; **102**: 1159-1164 [PMID: 1405967 DOI: 10.1288/00005537-199210000-00011]
 - 143 **Zou J**, Pyykkö I, Bjelke B, Dastidar P, Toppila E. Communication between the perilymphatic scalae and spiral ligament visualized by in vivo MRI. *Audiol Neurotol* 2005; **10**: 145-152 [PMID: 15724085 DOI: 10.1159/000084024]
 - 144 **Konishi M**, Kawamoto K, Izumikawa M, Kuriyama H, Yamashita T. Gene transfer into guinea pig cochlea using adeno-associated virus vectors. *J Gene Med* 2008; **10**: 610-618 [PMID: 18338819 DOI: 10.1002/jgm.1189]
 - 145 **Agterberg MJ**, Versnel H, van Dijk LM, de Groot JC, Klis SF. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. *J Assoc Res Otolaryngol* 2009; **10**: 355-367 [PMID: 19365690 DOI: 10.1007/s10162-009-0170-2]
 - 146 **Paasche G**, Bögel L, Leinung M, Lenarz T, Stöver T. Substance distribution in a cochlea model using different pump rates for cochlear implant drug delivery electrode prototypes. *Hear Res* 2006; **212**: 74-82 [PMID: 16337758 DOI: 10.1016/j.heares.2005.10.013]
 - 147 **Shepherd RK**, Xu J. A multichannel scala tympani electrode array incorporating a drug delivery system for chronic intracochlear infusion. *Hear Res* 2002; **172**: 92-98 [PMID: 12361871]
 - 148 **Zou J**, Poe D, Bjelke B, Pyykkö I. Visualization of inner ear disorders with MRI in vivo: from animal models to human application. *Acta Otolaryngol Suppl* 2009; **(560)**: 22-31 [PMID: 19221903 DOI: 10.1080/00016480902729850]
 - 149 **Zou J**, Pyykkö I, Counter SA, Klason T, Bretlau P, Bjelke B. In vivo observation of dynamic perilymph formation using 4.7 T MRI with gadolinium as a tracer. *Acta Otolaryngol* 2003; **123**: 910-915 [PMID: 14606591]
 - 150 **Zou J**, Poe D, Ramadan UA, Pyykkö I. Oval window transport of Gd-DOTA from rat middle ear to vestibulum and scala vestibuli visualized by in vivo magnetic resonance imaging. *Ann Otol Rhinol Laryngol* 2012; **121**: 119-128 [PMID: 22397222]
 - 151 **Rask-Andersen H**, Schrott-Fischer A, Pfaller K, Glueckert R. Perilymph/modiolar communication routes in the human cochlea. *Ear Hear* 2006; **27**: 457-465 [PMID: 16957497 DOI: 10.1097/01.aud.0000233864.32183.8100003446-200610000-00002]
 - 152 **Salt AN**, Plontke SK. Local inner-ear drug delivery and pharmacokinetics. *Drug Discov Today* 2005; **10**: 1299-1306 [PMID: 16214674 DOI: 10.1016/S1359-6446(05)03574-9]
 - 153 **Salt AN**, Ohyama K, Thalmann R. Radial communication between the perilymphatic scalae of the cochlea. II: Estimation by bolus injection of tracer into the sealed cochlea. *Hear Res* 1991; **56**: 37-43 [PMID: 1769923]
 - 154 **Salt AN**, Ma Y. Quantification of solute entry into cochlear perilymph through the round window membrane. *Hear Res* 2001; **154**: 88-97 [PMID: 11423219]
 - 155 **Laurell G**, Teixeira M, Sterkers O, Bagger-Sjöbäck D, Eksborg S, Lidman O, Ferrary E. Local administration of antioxidants to the inner ear. Kinetics and distribution (1). *Hear Res* 2002; **173**: 198-209 [PMID: 12372647]
 - 156 **Ulfendahl M**, Scarfone E, Flock A, Le Calvez S, Conradi P. Perilymphatic fluid compartments and intercellular spaces of the inner ear and the organ of Corti. *Neuroimage* 2000; **12**: 307-313 [PMID: 10944413 DOI: 10.1006/nimg.2000.0617S1053-8119(00)90617-7]
 - 157 **Zou J**, Sood R, Ranjan S, Poe D, Ramadan UA, Kinnunen PK, Pyykkö I. Manufacturing and in vivo inner ear visualization of MRI traceable liposome nanoparticles encapsulating gadolinium. *J Nanobiotechnology* 2010; **8**: 32 [PMID: 21167059 DOI: 10.1186/1477-3155-8-32]
 - 158 **Arbab AS**, Liu W, Frank JA. Cellular magnetic resonance imaging: current status and future prospects. *Expert Rev Med Devices* 2006; **3**: 427-439 [PMID: 16866640 DOI: 10.1586/17434440.3.4.427]
 - 159 **Mamani JB**, Malheiros JM, Cardoso EF, Tannús A, Silveira PH, Gamarra LF. In vivo magnetic resonance imaging tracking of C6 glioma cells labeled with superparamagnetic iron oxide nanoparticles. *Einstein (Sao Paulo)* ; **10**: 164-170 [PMID: 23052451]
 - 160 **Arbab AS**, Pandit SD, Anderson SA, Yocum GT, Bur M, Frenkel V, Khuu HM, Read EJ, Frank JA. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. *Stem Cells* 2006; **24**: 671-678 [PMID: 16179427 DOI: 10.1634/stemcells.2005-0017]
 - 161 **Wyatt C**, Soher B, Maccarini P, Charles HC, Stauffer P, Macfall J. Hyperthermia MRI temperature measurement: evaluation of measurement stabilisation strategies for extremity and breast tumours. *Int J Hyperthermia* 2009; **25**: 422-433 [PMID: 19925322 DOI: 10.1080/02656730903133762]
 - 162 **Thu MS**, Najbauer J, Kendall SE, Harutyunyan I, Sangalang N, Gutova M, Metz MZ, Garcia E, Frank RT, Kim SU, Moats RA, Aboody KS. Iron labeling and pre-clinical MRI visual-

- ization of therapeutic human neural stem cells in a murine glioma model. *PLoS One* 2009; **4**: e7218 [PMID: 19787043 DOI: 10.1371/journal.pone.0007218]
- 163 **Klose AD**, Beattie BJ, Dehghani H, Vider L, Le C, Ponomarev V, Blasberg R. In vivo bioluminescence tomography with a blocking-off finite-difference SP3 method and MRI/CT coregistration. *Med Phys* 2010; **37**: 329-338 [PMID: 20175496]
- 164 **Giesel FL**, Mehndiratta A, Locklin J, McAuliffe MJ, White S, Choyke PL, Knopp MV, Wood BJ, Haberkorn U, von Tengg-Kobligk H. Image fusion using CT, MRI and PET for treatment planning, navigation and follow up in percutaneous RFA. *Exp Oncol* 2009; **31**: 106-114 [PMID: 19550401]
- 165 **Yang Y**, Yang Y, Yanasak N, Schumacher A, Hu TC. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. *Magn Reson Med* 2010; **63**: 33-40 [PMID: 19953508]

P- Reviewer: Bugaj AM **S- Editor:** Gou SX
L- Editor: A **E- Editor:** Liu XM





INSTRUCTIONS TO AUTHORS

GENERAL INFORMATION

World Journal of Otorhinolaryngology (*World J Otorhinolaryngol*, *WJO*, online ISSN 2218-6247, DOI: 10.5319) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aims and scope

WJO covers topics concerning endoscopy, rhinology, pharyngology, laryngology, tracheo-esophagology, otology, tracheology, cancer, nasal symptomatology, congenital nasal diseases, inflammatory diseases of the external nose, rhinitis, allergic rhinitis, nasal polyps, nasal septal diseases, nasal bleeding, nasal or sinus foreign bodies, sinusitis, rhinogenic complications, diagnostic imaging, evidence-based medicine, epidemiology and nursing. The current columns of *WJO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of otorhinolaryngologic diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

WJO is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 43 OA clinical medical journals, including 42 in English, has a total of 15471 editorial board members or peer reviewers, and is a world first-class publisher.

Columns

The columns in the issues of *WJO* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplanta-

tion therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in otorhinolaryngology; (12) Brief Articles: To briefly report the novel and innovative findings in otorhinolaryngology; (13) Meta-Analysis: Covers the systematic review, mixed treatment comparison, meta regression, and overview of reviews, in order to summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJO*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of otorhinolaryngology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Otorhinolaryngology

ISSN

ISSN 2218-6247 (online)

Instructions to authors

Launch date

December 28, 2011

Frequency

Quarterly

Editor-in-chief

Tsutomu Nakashima, MD, PhD, Professor, Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

Steven J Wang, MD, FACS, Associate Professor in Residence, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, 2233 Post St, 3rd Floor-Box 1225, San Francisco, CA 94115, United States

Editorial office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

World Journal of Otorhinolaryngology

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381891

Fax: +86-10-85381893

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

Publisher

Baishideng Publishing Group Co., Limited

Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Telephone: +852-58042046

Fax: +852-31158812

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

Production center

Beijing Baishideng BioMed Scientific Co., Limited

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

Representative office

USA Office

8226 Regency Drive,

Pleasanton, CA 94588-3144, United States

Instructions to authors

Full instructions are available online at http://www.wjgnet.com/2218-6247/g_info_20100722180338.htm.

Indexed and Abstracted in

Digital Object Identifier.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homoge-

neous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJO* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted

for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2218-6247/office/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2218-6247/g_info_20100722180338.htm) before attempting to submit online.

For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to bjpgoffice@wjgnet.com, or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally

to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJO*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present P values where appropriate and must provide relevant data to illustrate how they were obtained, e.g., 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at:

Instructions to authors

http://www.wjgnet.com/2218-6247/g_info_list.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a $P < 0.05$, ^b $P < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of P values, ^c $P < 0.05$ and ^d $P < 0.01$ are used. A third series of P values can be expressed as ^e $P < 0.05$ and ^f $P < 0.01$. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK.** Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK,** Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P,** Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S,** Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC,** inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 $24.5 \mu\text{g/L}$; CO_2 volume fraction, 50 mL/L CO_2 , not 5% CO_2 ; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantumts can be found at: http://www.wjnet.com/2218-6247/g_info_20100724224620.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kbo I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjnet.com/esps/NavigationInfo.aspx?id=15>

RESUBMISSION OF THE REVISED MANUSCRIPTS

Please revise your article according to the revision policies of *WJO*. The revised version including manuscript and high-resolution image figures (if any) should be re-submitted online (<http://www.wjnet.com/2218-6247office/>). The author should send the copyright transfer letter, responses to the reviewers, English language Grade B certificate (for non-native speakers of English) and final manuscript checklist to wjotorhinology@wjnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjnet.com/2218-6247/g_info_20100724224507.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjnet.com/2218-6247/g_info_20100724224317.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

STATEMENT ABOUT ANONYMOUS PUBLICATION OF THE PEER REVIEWERS' COMMENTS

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

PUBLICATION FEE

WJO is an international, peer-reviewed, OA, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted case report must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article; Reprints fee: 350 USD per 100 reprints, including postage cost. Editorial, topic highlights, original articles, brief articles, book reviews and letters to the editor are published free of charge.



百世登
Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,

315-321 Lockhart Road, Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

